1 2 3 4	ALLEN RUBY (SBN 47109) LAW OFFICES OF ALLEN RUBY 125 South Market Street #1001 San Jose, CA 95113 Telephone: (408) 998-8500 ext. 204 Facsimile: (408) 998-8503	CRISTINA C. ARGUEDAS (SBN 87787) TED W. CASSMAN (SBN 98932) ARGUEDAS, CASSMAN & HEADLEY, LLP 803 Hearst Avenue Berkeley, CA 94710 Telephone: (510) 845-3000 Facsimile: (510) 845-3003
5	DENNIS P. RIORDAN (SBN 69320)	MICHAEL RAINS (SBN 91013)
6	DONALD M. HORGAN (SBN 121547) RIORDAN & HORGAN	RAINS, LUCIA & WILKINSON, LLP 2300 Contra Costa Blvd., Suite 230
7	523 Octavia Street San Francisco, CA 94102	Pleasant Hill, CA 94523 Telephone: (925) 609-1699
8	Telephone: (415) 431-3472 Facsimile: (415) 552-2703	Facsimile: (925) 609-1690 JAN 2 8 2009
9	Attorneys for Defendant BARRY LAMAR BONDS	CLIRK, U.S. DISTRICT COURT WORTHERN DISTRICT OF CALIFORNIA
10	BARRY LAMAR BUNDS	ALL CONSTRUCTION OF CALIFORNIA
11	UNITED STAT	TES DISTRICT COURTS OF CALIFORNIA
12	NORTHERN DIS	STRICT OF CALIFORNIA, CONTROL OF CALIFORNIA, CALIFORNIA, CONTROL OF
13	SAN FRA	NCISCO DIVISION
14	LINITED STATES OF AMEDICA	) Case No. CR 07 0732 SI
15	UNITED STATES OF AMERICA,	j l
16	Plaintiff,	) EXHIBITS A, B, AND C TO ) DEFENDANT'S MOTION IN ) LIMINE TO EXCLUDE EVIDENCE
17	vs.	
48	BARRY LAMAR BONDS,	) ) Date: TBA
19	Defendant.	<ul><li>) Time: TBA</li><li>) Judge: The Honorable Susan Illston</li></ul>
20		
21		
22		
23		
24		
25		
26		
27	EXHIBITS SUE	BMITTED
28		932
	A .	•

### INDEX TO EXHIBITS PROFFERED FOR FILING UNDER SEAL

Exhibit A December 12, 2008, correspondence from Allen Ruby to Jeffrey Finigan, Matthew Parella, and Jeffrey Nedrow December 26, 2008, correspondence from Jeffrey Finigan, Matthew Parella, and Exhibit B Jeffrey Nedrow to Allen Ruby Exhibit C Laboratory Tests

- 2.a. Calendars

1.

- **BALCO Log Sheets** 2.b.
- Handwritten Notes 2.c.

## **EXHIBIT A**

LAW OFFICES OF

### ALLEN RUBY

125 SOUTH MARKET STREET, SUITE 1001 SAN JOSE, CALIFORNIA 95113-2285

> EMAIL: rubylaw@allenrubylaw.com TELEPHONE: (408) 998-8500 FACSIMILE: (408) 998-8503

December 12, 2008

VIA EMAIL & HAND DELIVERY

Jeffrey R. Finigan, Esq.
Matthew A. Parrella, Esq.
Jeffrey D. Nedrow, Esq.
U.S. Attorney's Office
150 Almaden Boulevard, Suite 900
San Jose, CA 95113

Re: United States v Barry Bonds, No. CR 07-0732 SI

#### Gentlemen:

Pursuant to Paragraph 1 of the "Stipulation and Order for Pre-Trial Determination of Certain Evidentiary Issues" ("the Stipulation") Defendant hereby identifies evidence to which he will object if offered at trial. Although the Stipulation speaks to three categories of evidence, in an effort to be as specific as possible under the circumstances, we have further subdivided these categories – for example, documentary evidence is broken out into calendars, BALCO log sheets and handwritten notes.

We have also tried to be comprehensive in our objections, but if an item of evidence within one of the subdivisions below has escaped our notice, we would respectfully ask the Government to consider such item as among those to which the defense will object at trial, and to identify it in its response to this letter.

As the Stipulation recognizes, we can only object at this point to evidence which has been provided to us in discovery. The parties reserve their rights as to evidence discovered after this date.

Here are the categories and items to which we will object.

### 1. Laboratory Tests.

All laboratory tests allegedly attributed to a urine or blood sample of Barry Bonds or to a sample from any client of Greg Anderson or BALCO. An example is a copy of a Quest Diagnostics Laboratory Test with I.D. No. 100121, appended as Exhibit A. Such tests include but are not limited to the following laboratory reports:

Collection Date	Bates Stamp Number
February 25, 2000	BB002898
November 28, 2000	BB000127
January 19, 2001	BB000145
February 5, 2001	BB000129
February 19, 2001	BB000131
February 20, 2001	BB002955
July 7, 2001	BB000133
October 13, 2001	BB000134
November 8, 2001	BB000135
November 8, 2001	BB000147
November 8, 2001	BB001585
December 3, 2001	BB001589
January 8, 2002	BB001593
February 26, 2002	BB002900
April 12, 2002	BB001595
December 20, 2002	BB000136
February 6, 2003	BB000138
February 23, 2003	BB002961
Mary 28, 2003	BB000753 - BB000815
May 30, 2003	BB000123
June 4, 2003	BB000712 - BB000723
June 5, 2003	BB000143
August 31, 2003	BB002047
July 7, 2006	BB001895 - BB001899

If the government seeks to admit any of these laboratory results into evidence we will object on grounds of relevancy (Rule 402), lack of foundation and lack of authentication (Rule 901), lack of chain of custody, hearsay (Rule 802), undue prejudice (Rule 403) and fundamental unreliability of the evidence under the Due Process Clause.

### 2. Documentary Evidence

### a. Calendars.

All calendars allegedly reflecting the activities of Barry Bonds or any client of Greg Anderson or BALCO that were seized from BALCO or from Greg Anderson. An example is appended as Exhibit B. These include but are not limited to the following items in discovery:

<u>Date</u>	Bates Stamp Number
December 2001	BB000417, 12-246
January 2002	BB000418, 12-247
January 2002	BB000419, 12-248
February 2002	BB000420, 12-249
February 2002	BB000421, 12-250
March 2002	BB000422, 12-251
April 2002	11-227
May 2002	11-231
June 2002	11-229
September 2002	BB000424
November 2002	BB000430
November 2002	BB000437
December 2002	BB000425
December 2002	BB000431
December 2002	BB000438
January 2003	BB000426
January 2003	BB000432
January 2003	BB000439
January 2003	BB000445
February 2003	BB000427
February 2003	BB000433
February 2003	BB000440
February 2003	BB000446
April 2003	BB000423, 12-252
August 2003	11-223

If the government seeks to admit any of these calendars into evidence we will object on grounds of relevancy (Rule 402), lack of foundation and lack of authentication (Rule 901), hearsay (Rule 802), undue prejudice (Rule 403) and fundamental unreliability of the evidence under the Due Process Clause.

### b. BALCO Log Sheets

All internal BALCO documents allegedly recording (1) the receipt and/or transfer of urine and/or blood samples and/or (2) the results of laboratory tests for urine or blood samples. An example is appended as Exhibit C. These include but are not limited to the following items in discovery:

Bates Stamp Numbers

BB000114-BB000118

If the government seeks to admit any of these internal BALCO documents into evidence we will object on grounds of relevancy (Rule 402), lack of foundation and lack of authentication (Rule 901), hearsay (Rule 802), undue prejudice (Rule 403) and fundamental unreliability of the evidence under the Due Process Clause.

#### c. Handwritten Notes

All handwritten notations allegedly referring to Barry Bonds or to a client of Greg Anderson or BALCO where the author (1) is unidentified and/or (2) is not expected to testify at trial. An example is appended as Exhibit D. Such handwritten notes include but are not limited to the following:

### Bates Stamp Number

BB000113 23955 (11-202) 23826 23837 23844 (11-91)

If the government seeks to admit any of these handwritten notes into evidence we will object on grounds of relevancy (Rule 402), lack of foundation and lack of authentication (Rule 901), hearsay (Rule 802), undue prejudice (Rule 403) and fundamental unreliability of the evidence under the Due Process Clause.

### 3. Opinion Evidence On the Effects of Anabolic Steroids and Human Growth Hormone

### a. Opinion Evidence Concerning Steroids, THG, HGH, EPO, or Clomid

Any expert or lay opinion purporting to describe, whether as a general matter or as specifically attributable to Barry Bonds or another specific individual:

- (A) the physical, mental, psychological, or emotional effects of anabolic steroids, tetrahydrogestrinone, human growth hormone, erythropoietin, methenolone, nandrolone, or clomiphene;
  - (B) the meaning or interpretation of any laboratory test on urine or blood; or
- (C) the purpose or reason that a person or entity, such as BALCO, would request a particular laboratory test on a sample of urine or blood.

Examples are found in the grand jury testimony of Donald Catlin and Lawrence Bowers.

Additionally, any expert or lay opinion purporting to support or explain:

- (D) entries made on the calendars described in Section 2 above;
- (E) entries on the internal BALCO documents described in Section 3 above, or
- (F) the handwritten notes described in Section 4 above.

If the government seeks any such opinion into evidence we will object on the grounds that the evidence is not admissible under Rules 701 and 702. Where expert opinion is at issue, we will request a *Daubert* hearing.

### b. Witness Descriptions of Bonds' Physical, Behavioral and Emotional Characteristics

All testimony of percipient witnesses describing Barry Bonds' physical or emotional characteristics, or changes in his characteristics, (1) that the witness associates with the use of anabolic steroids or HGH and/or (2) that the government will argue was associated with the use of anabolic steroids or HGH.

This category includes but is not limited to a witness' alleged observation of acne on Bonds' back, testicle size or shrinkage, head size, hat size, hand size, foot size, sexual behavior, etc. Also included in this category are any alleged observations of angry or hostile behavior. Witnesses who have testified to or reported such observations include but are not limited to Kimberly Bell, Steven Hoskins and Stanley Conte.

If the government seeks to present testimony of a witness falling within this category, we will object on grounds of relevance (Rule 402), undue prejudice (Rule 403) lack of foundation and, where appropriate, improper opinion of a lay witness.

The following two categories of evidence are not specifically called out in the Stipulation. There are good arguments either way as to whether they should be addressed at this time. In the spirit of cooperation, we think the better course is to identify these items and apprise the Government of our objections, because we think the Court would appreciate an opportunity to have these issues briefed and heard well before trial.

### 4. Recorded Conversations in which Barry Bonds is not a Participant.

The discovery includes several tape-recorded conversations allegedly involving Steven Hoskins and others. In addition, the press has reported other conversations, including an alleged tape-recording of a phone conversation between Greg Anderson and Bobby McKercher.

If the government seeks to admit any of these recorded conversations into evidence we will object on grounds of relevancy (Rule 402), lack of foundation and lack of authentication (Rule 901), hearsay (Rule 802), unduly prejudicial (Rule 403) a violation of Title III and fundamental unreliability of the evidence under the Due Process Clause.

### 5. Phone Messages To Kim Bell

The discovery includes numerous voice mail messages allegedly left by Barry Bonds on Kimberly Bell's phone line. These voice mail messages include but are not limited to recordings found on a CD marked with bate stamp number B0109-1.

If the government seeks to introduce any of these recordings into evidence, we will object on grounds that the recordings are irrelevant (Rule 402) and unduly prejudicial (Rule 403).

Thank you.

Very Truly Yours,

ALLEN RUBY

AR:mg

cc: Cristina Arguedas, Esq.

Dennis Riordan, Esq.

Enclosures

I:\Bonds\C\Finigan Dec 12 08.doc

# **EXHIBIT** A

BATCH: 1

Quest Diagnostics Incorporated 7470 Mission Valley Road San Diego, CA 92:08 519.585.3000

PALCO (14059) BALCO, LABORATORY ATTN: VICTOR CONTE 1520 GALBRETE RD BURLINGAME, CA 94010

Donor Name/ID

Date Time Collected: 11/28/2000

Accession #: ¥2455799

Donor IC/SSN: NOT SPECIFIED

Other ID:

211

Received: 12/02/2000 10:52AM Reported: 12/06/2000 12:06 PM

Contact Name:

Specimen Type: URINE

Status: Final Report Request Type: Not Specified

Employer: NS

Collection Site: NOT SPECIFIED

ANABOLIC STEROID PANEL II

DHEA TESTOSTERONE EPITESTOSTERONE

10 ng/mL 14.0 ng/mL 10.5 ng/mL

T/E RATIO 1.3

T/E Ratio is considered positive at a value greater than 6. The following

anabolic agents were tested:

Bolasterone Eoldenone Clembuterol Clostebol Danazol

Methandienone Mibolerone Nancrolone Norethandrolone/Ethylestrenol

Dromostanolone

Oxandrolone Oxymesterone Oxymetholone Dehydrochloromethyltestosterone Dihydrotestosterone Stanozolol Stenbolone

Fluoxymesterone Formebolone Furazabol

Trenbolone Probenecid (masking agent) Mathyltastosterone

Masterclone Methandriol

Methenolone

and related compounds

ANABOLIC STEROIDS II

BOLASTERONE BOLDENONE CLOSTEBOL

Neg Neg Nea

REPORT CONTINUED ON NEXT FORM/PAGE

CONTINUED REPORT

BATCH: 1

Quest Diagnostics Incorporated 7479 Mission Valley Road San Diego, CA 92108 519.685.300C

PALCO (14059) BALCO LABORATORY ATTN: VICTOR CONTE 1520 GALBRETH RD BURLINGAME, CA 94010

Collected: 11/28/2000

Status: Final Report

Request Type: Not Specified

Date

Received: 12/02/2000 10:52AM

Reported: 12/05/2000 12:08 PM

Time

Donor Name/ID 100121 Accession #: Y2455799 Donor ID/SSN: NOT SPECIFIED Cther ID: NS

Contact Name:

Specimen Type: Employer: NS URINE

Collection Site: NOT SPECIFIED

ETHYLESTRENOL  FLUOXYMESTERONE  MESTEROLONE  METHENOLONE  METHYLTESTOSTERONE/METHANDRIOL  METHANDIENONE  NANDROLONE  NORETHANDROLONE/ETHYLESTRENOL  OXANDROLONE  OXYMESTERONE  OXYMESTERONE  OXYMETHOLONE  STANOZOLOL  STENBOLONE  PROBENECID (MASKING AGENT)  CLENBUTEROL  DANAZOL	
FLUOXYMESTERONE  MESTEROLONE  METHENOLONE  METHYLTESTOSTERONE/METHANDRIOL  METHANDIENONE  NANDROLONE  NANDROLONE  OXANDROLONE  OXYMESTERONE  OXYMESTERONE  OXYMESTERONE  OXYMETHOLONE  STANOZOLOL  STENBOLONE  PROBENECID (MASKING AGENT)  CLENBUTEROL  DANAZOL	eg
MESTEROLONE NO METHENOLONE ** POS METHYLTESTOSTERONE/METHANDRIOL NO METHANDIENONE ** POS NORETHANDROLONE/ETHYLESTRENOL OXANDROLONE NO OXANDROLONE NO OXYMESTERONE NO OXYMESTERONE NO STANOZOLOL NO STENBOLONE NO TRENBOLONE NO PROBENECID (MASKING AGENT) NO CLENBUTEROL NO DANAZOL NO	eg
METHENOLONE ** POS.  METHYLTESTOSTERONE/METHANDRIOL N.  METHANDIENONE ** POS.  NORETHANDROLONE/ETHYLESTRENOL N.  OXANDROLONE N.  OXYMESTERONE N.  OXYMESTERONE N.  STANOZOLOL N.  STENBOLONE N.  TRENBOLONE N.  PROBENECID (MASKING AGENT) N.  CLENBUTEROL N.	ag
METHYLTESTOSTERONE/METHANDRIOL NO METHANDIENONE NA POSSIBLE NO NORETHANDROLONE/ETHYLESTRENOL NO NORETHANDROLONE NO NORETHANDROLONE NO NORETHANDROLONE NO NO NO NORETHANDROLONE NO NO NO NORETHANDROLONE NO	eg
METHANDIENONE NAME NAME NAME NAME NAME NAME NAME NA	TIVE **
NANDROLONE ** POS. NORETHANDROLONE/ETHYLESTRENOL NO. OXANDROLONE NO. OXYMESTERONE NO. OXYMETHOLONE NO. STANOZOLOL NO. STENBOLONE NO. TRENBOLONE NO. PROBENECID (MASKING AGENT) NO. CLENBUTEROL NO.	∋g
NORETHANDROLONE/ETHYLESTRENOL NO NANDROLONE NO OXANDROLONE NO OXYMESTERONE NO STANOZOLOL NO TRENBOLONE NO TRENBOLONE NO PROBENECID (MASKING AGENT) NO CLENBUTEROL NA OXANDROLONE NO CLENBUTEROL NA OXANDROLONE NA OXANDR	∍g
OXANDROLONE NO OXYMESTERONE NO OXYMETHOLONE NO STANOZOLOL NO STENBOLONE NO TRENBOLONE NO PROBENECID (MASKING AGENT) NO CLENBUTEROL NO DANAZOL NO	TIVE **
OXYMESTERONE NO STANOZOLOL NO STENBOLONE NO TRENBOLONE NO PROBENECID (MASKING AGENT) NO CLENBUTEROL NA DANAZOL	∍g
OXYMETHOLONE NO STANOZOLOL NO STANOZOLOL NO STENBOLONE NO TRENBOLONE NO PROBENECID (MASKING AGENT) NO CLENBUTEROL NO DANAZOL NO	∍g
STANOZOLOL NO STENBOLONE NO TRENBOLONE NO PROBENECID (MASKING AGENT) NO CLENBUTEROL NO DANAZOL NO	eg
STENBOLONE NO TRENBOLONE NO PROBENECID (MASKING AGENT) NO CLENBUTEROL NO DANAZOL NO	eg 💮
TRENBOLONE NO PROBENECID (MASKING AGENT) NO CLENBUTEROL NO DANAZOL NO	eg
PROBENECID (MASKING AGENT) NO CLENBUTEROL NO DANAZOL NO	∍g
CLENBUTEROL NO DANA ZOL NO	ag .
DANA ZOL Ne	eg .
	eg
<u> </u>	ag .
	∍g
	eg
FURAZABOL Ne	Pα
MIBOLERONE	-

Accession #: Y2455799

## EXHIBIT B

30	23	16	9	2	Dece
31 025 025	166 T 200mg 24 2 166 T 200mg	17	10 10 11 10 100009	ω	ember
	2	18	10 11 10 11	4 Checar	December 2001
ان انه ان	, 25 G 26	19	.75 G	O <sub>1</sub>	WED
	27 Clear	20	C II	6 Char. or	UHT
	28	21 21	. 25 G	. 7	55 (A) - (A)
	29	. 22	15	8 H	SAT
				S G N D P	
		en e	-246		

# EXHIBIT C

Initials Date Prepared By Approved By HI WILSON JONES G7506 ColumniWrit - II Rutio E93 てき らて Barry B 142/1 10th Du 113 10,5 25 2/4/01 Ю 5 Dayson 17 Dons off 1 xx x404 **3**.a 5/8/41 ガカト Charlie 100137 Dre TVEN Post 500 60 12 13 14 15 Fluin 17 100140 4Days on 3111¢1 724h Tre Þ 100 159 112ay on 350 2011001100 19 45 19 Post - Dals 10017a TOC e pays 21 21 100146 ۱۲| 22 77o, 22 12,5 <u>ر</u> 100157 Day of 24 Tom 25 25 42/2 5 Pie 20 5 ŝ P(4 65 15 1 Day 27 45 D 4000 35 29 29 30 30 `τ<sup>-</sup>. ΄: Pre LOCILER 3.8 101/67 44 33 5.3 14 1CC (7'1 100173 31.1 35 11/01 X 3€ Æ 37 ۲, CAIVIN 30 33.7 3/26/01 11/168 95 100176 8 41.0 H.O 4 Doses 181001

# EXHIBIT D

## BARRY

\$BLOOD TEST NOV 29, FEB 14, MARCH 28.

# G" I Box off Seeson & 2 Box John

A Depo test Cyp 3 Bothles aft & Res Section

\* Clear & CREAM off & Reg Season \$200

\$ Clamifeno est & Reg 100 pills

TETTE

\$ 2500

## **EXHIBIT B**



### U.S. Department of Justice

### United States Attorney Northern District of California

11th Floor, Federal Building 450 Golden Gate Avenue, Box 36055 San Francisco, California 94102 (415) 436-7200 FAX:(415) 436-7234

December 26, 2008

VIA EMAIL & MAIL
Allen Ruby, Esq.
Law Offices of Allen Ruby
125 South Market Street, Suite 1001
San Jose, CA 95113

Re:

United States v. Barry L. Bonds

CR 07-0732 SI

Dear Mr. Ruby,

This responds to your letter of December 12, 2008. Preliminarily, we note that the Stipulation requires the defense to identify objectionable items of evidence with reasonable particularity. Accordingly, your request that the government, in its response, identify additional items that "escaped [your] notice" is inappropriate.

This letter only addresses evidentiary issues related to the government's case-in-chief and the government's responses herein are therefore subject to change depending upon how the case develops from this point forward and during any defense cross-examination or the defense case-in-chief.

We address your objections in the order you made them and reserve the right to make additional arguments and raise other bases for admissibility of the evidence identified in your letter. With respect to your boilerplate objection pursuant to FRE 403, the government's response is that none of the evidence in your letter is unduly prejudicial. All of the evidence is extremely probative and tends to prove guilt, which does not equate with undue prejudice.

### 1. Laboratory Tests

The laboratory tests identified in your letter are relevant because they have a tendency to make facts of consequence, e.g. knowledgeable use of steroids and other substances, to the charges more probable than without the evidence. They also corroborate witnesses connected with the tests. The tests will be authenticated by employees from the various labs that conducted the tests. The chain of custody will also be established by the various labs that performed the tests, statements by individuals who submitted the samples, statements by individuals who assisted in obtaining the samples (e.g. Dr. Ting), and agents who transported the samples. Without conceding the existence of any missing links in the chain of custody, to the extent there are any at the time this evidence is offered, they would only effect the weight of the evidence, not

the admissibility. The lab tests are admissible as business records pursuant to FRE 803(6). Your objection based on "fundamental unreliability of the evidence under the Due Process Clause" is vague and fails to articulate a specific manner in which it is somehow different from or not encompassed within the other listed objections.

### 2. Documentary Evidence

#### a. Calendars

The calendars are relevant because they have a tendency to make facts of consequence, e.g. knowledgeable use of steroids and other substances, to the charges more probable than without the evidence. They also corroborate witnesses connected with the calendars. The calendars will be authenticated by witness testimony, including, but not limited to, testimony by athletes who received hard copies of calendars from Anderson and testimony by agents related to where the calendars were found. The calendars are potentially admissible under four hearsay exceptions: (1) as statements against Greg Anderson's interests pursuant to FRE 804(b)(3); (2) as statements of a co-conspirator pursuant to FRE 801(d)(2)(E); (3) as business records pursuant to FRE 803(6); and (4) pursuant to the residual exception in FRE 807. Along these lines, please consider this notice of the government's intent to offer this evidence pursuant to FRE 807 on the grounds that the calendars are evidence of material facts, more probative than other evidence the government can procure, and the general purposes of the FRE and the interests of justice will best be served by admitting them. Your objection based on "fundamental unreliability of the evidence under the Due Process Clause" is vague and fails to articulate a specific manner in which it is somehow different from or not encompassed within the other listed objections.

### b. BALCO Log Sheets

The log sheets are relevant because they have a tendency to make facts of consequence, e.g. knowledgeable use of steroids and other substances, to the charges more probable than without the evidence. They also corroborate witnesses connected with the log sheets. The log sheets will be authenticated by James Valente. The log sheets are potentially admissible under four hearsay exceptions: (1) as statements against James Valente's interests pursuant to FRE 804(b)(3); (2) as statements of a co-conspirator pursuant to FRE 801(d)(2)(E); (3) as business records pursuant to FRE 803(6); and (4) pursuant to the residual exception in FRE 807. Along these lines, please consider this notice of the government's intent to offer this evidence pursuant to FRE 807 on the grounds that the log sheets are evidence of material facts, more probative than other evidence the government can procure, and the general purposes of the FRE and the interests of justice will best be served by admitting them. Your objection based on "fundamental unreliability of the evidence under the Due Process Clause" is vague and fails to articulate a specific manner in which it is somehow different from or not encompassed within the other listed objections.

#### c. Handwritten Notes

Greg Anderson's handwritten notes are relevant because they have a tendency to make facts of consequence, e.g. knowledgeable use of steroids and other substances, to the charges more probable than without the evidence. Greg Anderson's handwritten notes will be authenticated by witness testimony, including, but not necessarily limited to, testimony related to where they were found. Greg Anderson's handwritten notes are potentially admissible under at least two hearsay exceptions: (1) as statements against Greg Anderson's interests pursuant to FRE 804(b)(3); and (2) as statements of a co-conspirator pursuant to FRE 801(d)(2)(E). Your objection based on "fundamental unreliability of the evidence under the Due Process Clause" is vague and fails to articulate a specific manner in which it is somehow different from or not encompassed within the other listed objections.

### 3. Opinion Evidence re Anabolic Steroids and HGH

The parties have already discussed multiple times the fact that the government intends to offer testimony from Donald Catlin and Lawrence Bowers pursuant to FRE 702 and the government will provide notice of expert testimony in due course. Their qualifications and general substance of their testimonies are contained within their grand jury transcripts. The government's experts on the topics of steroid use, its effects, and the practices of labs that send out samples for steroid testing will testify based on specialized knowledge which is likely to assist the jury in understanding the evidence and determining facts at issue in the case. This evidence is reliable, relevant, and admissible. To the extent the aforementioned experts rely upon statements by any other witness related to the defendant's physical characteristics or changes thereto, those statements are relevant and admissible. Likewise, to the extent the aforementioned experts or any other witness provide testimony that makes any other witness' statement related to the defendant's physical characteristics or changes thereto relevant, those statements are admissible. For example, Lawrence Bowers may testify that one common effect of steroid use is increased muscle mass. Presumably he will not need to rely upon any statement from another witness to draw that conclusion. Nevertheless, if another witness can testify that the defendant experienced an increase in muscle mass during a relevant time period, that observation will be admissible.

You have not identified with any particularity any lay opinions you object to.

### 4. Recorded Conversations

The recorded conversation between Greg Anderson and Steve Hoskins, wherein Anderson describes injecting the defendant, having the ability to obtain and utilize inside information about MLB's random drug testing to the defendant's benefit, and the undetectable nature of what Anderson had been doing for the defendant is undeniably relevant. Mr. Hoskins can authenticate the recording. The recording is potentially admissible under two hearsay exceptions: (1) as a statement against Greg Anderson's interests pursuant to FRE 804(b)(3); and

(2) pursuant to the residual exception in FRE 807. Along these lines, please consider this notice of the government's intent to offer this evidence (*i.e.*, the recording itself or Mr. Hoskins' testimony regarding the conversation in the event the Court rules the recording is inadmissible for any reason) pursuant to FRE 807 on the grounds that the recording is evidence of material facts, more probative than other evidence the government can procure, and the general purposes of the FRE and the interests of justice will best be served by admitting the recording. The recording does not violate Title III pursuant to 18 U.S.C. § 2511(2)(d). Furthermore, the defendant was not a party to the conversation and therefore is not an aggrieved party and the government played no role in the recording. Your objection based on "fundamental unreliability of the evidence under the Due Process Clause" is vague and fails to articulate a specific manner in which it is somehow different from or not encompassed within the other listed objections.

### 5. Phone Messages to Kim Bell

The government does not concede that the recorded messages the defendant left for Kimberly Bell, many of which were extremely hostile and threatening, are irrelevant or unduly prejudicial. Nevertheless, at this point in time, the government does not intend to offer those recordings into evidence during its case-in-chief. The government reserves its right to reconsider its position on this issue depending upon how the case develops from this point forward and, of course, in the event the defense opens the door to this evidence in any manner.


Sincerely,

JOSEPH P. RUSSONIELLO United States Attorney

By: \_\_\_\_\_\_

MATTHEW A. PARRELLA JEFFREY D. NEDROW JEFFREY R. FINIGAN Assistant United States Attorneys

## **EXHIBIT C**



LABORATORY DARLY SUMMARY
MR : (0000)0104-82-47
ACCT: 71535991
NAME: BONDER, BARRY
AGE : 35 YRS SEX : M
LOC : DIAG ROOM :
PHYSICIAN: REFERRED OUT PT

02/26/00 0938 ADMIT: 02/25/00

ST. JOSEPH'S HOSPITAL & MEDICAL CENTER 350 West Thomas Road Phoenix, Az 85013 Phone: (502)406-3410

			HEMATOLOGY		]
	DATE: 02	25/00			
		420			
OMPLETE BLOC				REFERENCE	UNIT
LATELET	D COURT	260		150-450	TH/UL
BC		6.6		3.6-11.1	
BC	9	3.36		4,27-5,49	
EMOGLOBIN		4.5		12.9-16.1	
EMATOCRIT		2.9		37.7-46.5	
CV		80		79-95	PL
CH	2	7.1L		28.0-32.0	PG
CHC		3.8		32.0-36.0	
DW		4.6H		11.5-14.5	UNITE
OLYS & (AUTO	)	52L		56-65	•
YMPHS . (AUT	Ó)	39H		25-35	*
ONO & (AUTO)		7		1-10	•
OS & (AUTO)		2		0-5	
ASOS & (AUTO		0		0-1	•
OLYS ABS		3.5		02.0-08.0	TH/UL
YMPHS ABS		2.6		1.5-4.0	TH/UL
ONOS ABS		0.5		0.1-2.0	TH/UL
OS ABS		0.1		0.0-0.7	TH/UL
asos abs		0.0		0.0-0.2	_TH/UL
			CHEMISTRY		
	DATE: 02/	25/00			_
		420			
				REFERENCE	UNIT
MEMISTRY PAR	els .				
ODIUM		139		134-144	MEQ/L
ODIUM (09/29					
	RANGE CHANG	ED 9/29/99.	•		
OTASSIUM		4.4	•	3.6-5.1	MBQ/L
HLORIDE		104		101-111	MEQ/L
:02		29		22-32 8-20	MEQ/L MG/DL
UN		20		0.7-1.2	MG/DL
REATININE		1.9H		74-118	MG/DL
LUCOSE		94 9.2		8.9-10.3	MG/DL
ALCIUM	_				G/DL
OTAL PROTEIN		6.5		6.1-7.9 3.5-4.8	G/DL G/DL
LBUKIN		3.7			
LK PHOS		41		38-126	U/L MG/DL
ILIRUBIN TOT	AL	0.7		0.4-2.0	
GOT		48H		15-41	U/L
ENERAL CHRIS SA (ABBOTT A		17		0.10-4.00	NG/ML
SA (ABBOIT A				5.15 4.55	
	High				
<u>= Low. H =</u> IR-48C (10/98		_	CONTINUED	PAGE	1

SFG (S.C.) 0821

	<b>)</b>	
·		

BATCH: 1

Quest Diagnostics Incorporated 7470 Mission Valley Road San Diego, CA 92:08

619.585.3000

PALCO (14059) BALCO LABORATORY ACTN: VICTOR CONTE 1920 GALBRETE RD BURLINGAME, CA 94010

Donor Name/ID 100121

Accession #: Y2455799
Donor IC/SSN: NOT SPECIFIED

Other ID: NS

Contact Name: Specimen Type: URINE

Employer: NS

Collection Site: NOT SPECIFIED

Date Time

Collected: 11/28/2000

Received: 12/02/2000 10:52AM Reported: 12/05/2000 12:06 PM

Status: Final Report Request Type: Not Specified

ANABOLIC STEROID PANEL II

DELA TESTOSTERONE DHEA EPITESTOSTERONE

T/E RATIO

14.0 10.5 1.3

10

ng/mL ng/mL

ng/mL

T/E Ratio is considered positive at a value greater than 6. The following

anabolic agents were tested:

Bolasterone Eoldenone Clembuterol

Clostebol Danazol

Dromostanolone

Dehydrochloromethyltestosterone Dihydrotestosterone Fluoxymesterone Formebolone

Furazabol Mesterclone

Methandriol

Methandienone

Mibolerone Nandrolone

Norethandrolone/Ethylestrenol

Oxandrolone Oxymesterona Oxymetholone Stanozolol Stenbolone Trenbolone

Probenecid (masking agent)

Mathyltestosterone

Methenclone

and related compounds

ANABOLIC STERGIDS II

BOLASTERONE BOLDENONE CLOSTEBUL

Neg Neg Neg

REPORT CONTINUED ON NEXT FORM/ PAGE

CONTINUED REPORT

Quest Diagnostics Incorporated 7470 Mission Valley Road San Diego, CA 92108

519.685.3000

PALCO (14059) BALCO LABORATORY ATTN: VICTOR CONTE 1520 GALBRETH RD

BURLINGAME, CA 94010

BATCH: 1

Date

Received: 12/02/2000 10:52AM

Request Type: Not Specified

Reported: 12/06/2000 12:08 PM

Final Report

Collected: 11/28/2008

Status:

Time

Ponor Name/ID 100121
Accession #: Y2455799
Donor ID/SSN: NOT SPECIFIED
Other ID: NS
Contact Name:
Specimen Type: URINE
Employer: NS
Collection Site: NOT SPECIFIED

DEHYDROCHLOROMETHYLTESTOSTERONE ETHYLESTRENOL Neg FLUOXYMESTERONE Neg MESTEROLONE Neg METHENOLONE \*\* POSITIVE \*\* METHYLTESTOSTERONE/METHANDRIOL Neg Neg METHANDIENONE NANDROLONE POSITIVE \*\* NORETHANDROLONE/ETHYLESTRENOL Neg OXANDROLONE Neg OXYMESTERONE Neg OXYMETHOLONE Neq STANOZOLOL Neg STENBOLONE Меg TRENBOLONE Neg PROBENECID (MASKING AGENT) Neg CLENBUTEROL Neg Neg DANAZOL DROMOSTANOLONE Neg Neg FORMEBOLONE **FURAZABOL** Neg MIBOLERONE Neg

Accession #: Y2455799



REF:

SPECIALTY# 098-6186805 CLIENT # 44003

NAME: B, B

PHYSICIAN: GOLOMAN, BRIAN H

NOTES:

PATIENT ID: 00216 SPECIMEN ID: 60216

BALCO LABS

ATTN: JIM VALENTE 1520 GILBREATH ROAD

BURLINGAME

CA 94010

DOB: 07/24/64 AGE: 36 Years

SEX: Male

DRAWN: RECEIVED: PRINTED .

101/19/01 15:00 01/22/01 17:09 01/26/01 08:40

FINAL REPORT: 01/26/01 08:40

FINAL

TEST NAME RESULTS ------\_ \_ \_ \_ \_ \_

REFERENCE RANGE

TESTOSTERONE, FREE & TOTAL

Testosterone Total Testosterone Free

730

ng/dL

(241 - 827)

> 5.00 ng/dl

REFERENCE RANGES for Testosterone Free

Males:

20-49 yrs . . . . 0.95-4.30 ng/dL > 50 yrs . . . . 0.80-3.50 ng/dL

Ovulating . . . Up to 0.38 ng/dL Postmenopausal . . Up to 0.13 ng/dL

Free Testosterone

% of total (0.32-0.50) .

The percentage of total testosterone in unbound state (% free testosterone) cannot be calculated since the free testosterone level is greater than the highest detectable concentration.

COMPLETE BLOOD COUNT

WBC	7.9		thou/cu mm	(4.0-11.0)
RBC	5.34		mil/cu mm	(4.50-6.00)
Нgb	14.0		g/dL	(13.5-18.0)
Ect	44.9		<b>%</b>	(40.0 - 54.0)
MCV .	8 4		fL	(80-96)
MCH	2 6		pg	(26-34)
MCEC	3 1		g/dL	(31-37)
Platelets	5 8 E		thou/cu mm	(150-400)
Segmented Neutrophils	7 3	H	ફ	(50-70)
Basophils	0		o o	(< 2)
Ecsinophils	3		8	(< 6)
Lymphocytes	2.3		ફ	(20 - 40)
Monocytes	0		e e	(< 8)
REC Morphology	Normal			

F 4 4 C O 8

19242

1

Riotringn Page 2

Aller Zalenith, un Albert Planingvitch, M.O. Ph. 2



SPECIALTY# 098-5186805 CLIENT # 44008

NAME:

B, B

PBYSICIAN: GOLDMAN, BRIAN H

NOTES:

PATIENT ID: 00216 SPECIMEN ID: 00216

BALCO LAES

ATTN: JIM VALENTE 1520 GILBREATH ROAD

BURLINGAME

CA 94010

DOB: 07/24/64 AGE: 36 Years

SEX: Male

DRAWN: RECEIVED: 01/19/01 15:00

PRINTED:

01/22/01 17:09 01/26/01 08:40

FINAL REPORT:

01/26/01 08:40

FINAL

TEST NAME RESULTS REFERENCE RANGE \_ \_ \_ \_ \_ \_ \_ \_ \_ \_ \_\_\_\_\_

### AUTOANTIBODY CONFIRMATION [ IE]

\_\_\_\_\_\_

Ul RNP/snRNP IgG Autoabs Sm IgG Autoabs

Scl-70 IgG Autoabs

Not detected Not detected

Not detected

Not detected

Not detected Not detected

This test result or one or more of its components was developed and its performance characteristics determined by Specialty Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary.

TACTATE	DEHYDROGENASE
$D \times C \times U \times D$	DENTIFICATIVAT

Lactate Dehydrogenase (	LDE)	208	O/L	( <	251)
CHOLESTEROL EVALUATION		•			
Triglycerides Cholesterol, Total		195 178 20 E	mg/dL mg/dL mg/dL	(<	200) 200) 34)
LDL-C (Calc) Cholesterol/HDL-C Ratio	<	132 н	mg/dL	(<	130)


F44008 19242 1 Ricari (Mari Page 3

لالله بالترسيلية جمياني Albam Egginoviton, N. D. Ph.S.



7470 Mission Valley Fload San Diego, CA 92108 1 (600) 647-2827 Client Services 1 (600) 446-4728 BALCO LABORATORY ATTN: VICTOR CONTE 1520 GALBRETH ED BURLINGAME, CA 94010

Patient Name/Specimen LO : 1 必 む に 4 ら	Accession No. 1	, M	Cate 02/05/2021	Time
		Callected 12	62 (83) 2882	
PRINCIPLED NOT SPECIFIED	Qtner∃D ओळ	Received	02/05/3082	1,489
Requesting Physician/Contact Name	Specimen Type	Recorded	90/11/1991	02 81 P
RequestType: Employer: NS Collection Site (MOT SPECIFIED) Remarks		Status	FIMAL PERCA	
ADABOLLO STEROID FAMEL II DHEA TESTOSTERONE EPITESIOSTERONE T/E RATIO TESTOSTERONE AND EPITES	41 0.0 0.0 0.0 STOSTERONE APE NOT DE	ng/mL ng/mL ng/mL TECTED		
mum mereta 3 % akhadadak		castan thes	ennamentaria. Sennamentaria	
T/E Ratio is considered anapolic agents were test Bolasterone	ediv	reater than handienone:	6. The folio	Paing
Boldenoue		olerone		
Clenbuterol	Grant Control of the state of t	drolome		
Clostepol			e/Etnylestrend	91
Danazol		ndrolone		_
Dromostancione		mesterone		
Dehydrochloromethyltestos		metholone		
Dihydrotestosterons	Sta.	nozolol		
Fluoxymesterone	- And	nbolone		
Formebolone		nbələnə		
Furazabol		cenebid (mas		
Mastarolone		nyitestoste:	202	
Methendriel	Meti	nemolone		
and related compounds				
NABOLIC STEROIDS II				
BOLASTERONE	Neg			
BOLDENOMET	Neg			
CLOSTEPOL	in Neg :			
DEHYDROCHLOROMETHYLIESTOS	TERONE Neg			
ZTHYLESTRENCL	Neg :			
FLOOKYMESTERONE	Neg Neg			
MESTURGLONE	Heg	٠		
MEIHENOLONE	** POSITIVE **			
METHYLTESTOSTEFONE/METHAM SMOMENDARFIEM				
MAND FOLONE  MAND FOLONE	Neg Neg			:
- MANDFOLDME/ETHYLESTS				
OXANDROLONS	Neg Neg			
	Neg			
ONUMBETERCHE				



7470 Miss on Valley Road San Diego, CA 92108 1 (800) 647-2927 Client Services 1 (800) 445-4728

BALCO LABOFATORY ATIN: VICTOR CONTR 1510 GALEFETH PD BUFLINGAME, OR 94010

Paten: Name/Specimen I.D	Acrossina No		Date	Time
100145	Accession Mo Y 2 5 3 4 1 2 5	Collected: W	02:03/2001	
Patient I.D./SSN	Other I.D			
NOT EPSCIFIED	PiΣ	Received:	31/35/19 <b>0</b> 1	1:41위()
Requesting Physician/Contact Name	Specimen Type		0041 .5551 .	
Bookest Type Employet: NS	· · · · ·	Faponed	- 0011142001 : - Final Fired	
		Status	8 - 14 5 L - 15 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	_
Collection Site. For Special Led		'		
NOT SPECIFIED)				

_	ರಿಸುವ ನೆಪ್ಪದ ವಿಶ್ವಾಣದ	·ieg
	STANOIOLOL	Neg
	STEMBOLONE	Nëg
	TEBNECIONE	Neg
	FECSENECID (MASKING AGENT)	Med
	CLENBUTEFOL	Meg
	DAMAZOZ	Neg
	DECMOSTANCLONE	Neg
	FORMESOLONE	Neg
	FURAZABOL	Neg
	MIEGLERONE	Neg
		- Part Title 発しaEst

.

FRGM 60760130

COFEER) SEEST OFFCOTERY PAGE 2 OF 3

EATCH: 1

Ouest Diagnostics Incorporated 7470 Mission Valley Road San Diego, CA 92108

617.586.3000

PALCO (14059)

BALCO LABORATORY

ATTN: VICTOR CONTE

1520 GALERETH RD

BURLINGAME, CA 94010

Donor Name/ID 100155

Accession #: Y2537974

Denor IC/SSN: NOT SPECIFIED

Other IO: NS

Contact Name: Specimen Type: URINE

Employer: NS

Collection Site: NOT SPECIFIED

Date Time

Collected: 02/19/2001

Received: 02/22.2001 10:13AM Reported: 02/23/2001 08:54 AM

Status: Final Report Request Type: Not Specified

AMABOLIO STERDID PANEL II

DHEA 10 ng/mL
TESTOSTERONE 6.0 ng/mL
EPITESTOSTERONE 8.0 ng/mL
TESTOSTERONE AND EPITESTOSTERONE ARE NOT DETECTED.

T/Z Ratio is considered positive at a value greater than 6. The following

anabolic agents were tested:

Bolasterone Methandienone
Eoldenone Mibolarone
Clembutarol Nandrolone

Clostebol Norethandrolone/Ethylestrenol

Danazol Oxandrolone
Dromostanolone Oxymesterone
Dehydrochloromethyltestosterone Oxymetholone
Dihydrotestosterone Stanozolol
Flucxymesterone Stenbolone
Formebolone Trenbolone

Furazabol Probehecid (masking agent,

Mesterolone Methyltestosterone

Methandriol Methandlone

and related compounds

ANABOLIC STEROIDS II

BOLASTERONE Neg BOLDENONE Neg

REPORT CONTINUED ON MEXT FORM/PAGE

EALCO (14059)

CONTINUED REPORT

BATCH: 1

Quest Diagnostics Incorporated 7479 Mission Valley Road San Diago, CA 92186 619.886.3000

BALGO LABORATORY ATTN: VICTOR CONTE 1520 GALBRETH RD BURLINGAME, CA 94810

Received: 02/20/2001 12:13AM

Reported: 02/23/2001 05:54 AM

Date Collected: 03/19.233!

Status: Final Report


Request Type: Not Specified

Donor Name/ID 100155 Accession #: Y2537974 Donor ID/SSN: NOT SPECIFIED Other ID: NS Contact Name: Specimen Type: URINE Employer: NS Collection Site: NOT SPECIFIED CLOSTEBOL Neg DEHYDROCHLOROMETHYLTESTOSTERONE Neg ETHTLESTPENOL Nec Neg FLUOXYMESTERONE MESTEROLONE Neg METHENOLONE \*\* POSITIVE \*\* METEYLTESTOSTERONE/METHANDRIOL Neg Neg METHANDIENONE \*\* POSITIVE \*\* NANDROLONE NORETHANDROLONE/ETHYLESTRENOL Neg CXANDROLONE Меç OXYMESTEROME Neg OXYMETHOLONE Neg STANG2OLOL Neg STENECLONE Neg TRENEOLONE Neg PROBENECIO (MASKING AGENT) Neg CLENBUTEROL Neg DANAZOL Neg DROMOSTANGLONE Neg FORMESOLONE Neg FURA ZABOL Neg

Accession #: Y2537574

MISOLERONE

Neg



350 WEST THOMAS ROAD

Phoenix, AZ 85013 Phone: (602)406-3410

MR : (0000)0104-82-47

ACCT: 73327892 NAME: BONDS, BARRY

AGE : 36 YRS SEX : M LABM LOC : ROOM : PHYSICIAN: REFERRED OUT PT

LABORATORY TEMPO Y CHART COPY (Replace with next daily/weekly chart)

02/26/01 0502 ADMIT: 02/20/01

DATE:	02/24/01
TIME:	1328

				REFERENCE	UNIT
COMPLETE BLOOD	COUNT				
PLATELET	395			150-450	TH/UL
WBC	10.1			3.6-11.1	TH/UL
RBC	5.50H			4.27-5.49	
HEMOGLOBIN	14.2			12.9-16.1	
HEMATOCRIT	42.1			37.7-46.5	
MCV	771			79-95	FL
MCH	25.9L			28.0-32.0	PG
MCHC	33.8			32.0-36.0	GM/DL
RDW	15.6H			11.5-14.5	UNITS
POLYS % (AUTO)	64			56-65	8
LYMPHS % (AUTO)	29			25-35	8
MONO % (AUTO)	6			1-10	<b>8</b>
EOS & (AUTO)				0-5	8
BASOS % (AUTO)	1			0-1	8
POLYS ABS	06.5			 02.0-08.0	TH/UL
LYMPHS ABS	2.9			1.5-4.0	TH/UL
MONOS ABS	0.6			0.1-2.0	TH/UL
EOS ABS	0.1			0.0-0.7	TH/UL
BASOS ABS	0.0			 0.0-0.2	TH/UL
		CHE	MISTRY	 	

# CHEMISIRY

'	DATE: TIME:	02/24/01 1328				•		
							REFERENCE	UNIT
CHEMISTRY	Panels							
SODIUM	Asset Control	139	· 1.1	. ** *		2.5	134-144	MEQ/L
POTASSIUM		4.3					3.6-5.1	MEQ/L
CHLORIDE	P	103		din,			101-111	MEQ/L
CO2		28					22-32	MEQ/L
BUN		26H			10 % 2 1 4		8-20	MG/DL
CREATININE		1.8H					0.7-1.2	MG/DL
GLUCOSE	100	87			and the second	Seley E	74-118	MG/DL
ANION GAP		8					7-15	
CALCIUM		9.7					8.9-10.3	MG/DL
TOTAL PROT	'EIN	7.5				•	6.1-7.9	G/DL
ALBUMIN	. "	3.9					3.5-4.8	G/DL
ALK PHOS		48					38-126	U/L
BILIRUBIN	TOTAL	1.0					0.4-2.0	MG/DL
BILI DIREC		.15					.1050	MG/DL
SGOT		<b>75</b> H					15-41	U/L
SGPT		68H					17-63	U/L

SFG (S.C.) 0877

L = Low. H = HighMR-48C (10/98) ROY IAN DAVIS, M.D.-MEDICAL DIRECTOR CHAIRMAN OF DEPARTMENT OF PATHOLOGY

-END OF REPORT-

PAGE E. SMITH COLLUM, M.D. - DIRECTOR CLINICAL LABORATORY SERVICES

Hiddea: , 

EATIM: 1

, BALCO (14059) Quest Diagnostics Incorporated 7470 Mission Valley Road BALCO LABORATORY San Diego, CA 92108 ACTN'S VICTOR CONTE 619,685,3000 1530 GALBRETS RD EURLINGAME, CA 94010

Donor Name/ID 100321 Date Time Accession #: Y2733161 Collected: CT/88 189: Donot IC/SSN: NOT SPECIFIED Padelved: 07/29/1901 4:087M NS Other IC: Reported: 07/11/2001 08:85 AM Contact Name: Status: Final Seport Specimen Type: URINE Request Type: Not Specified

Employer: MS Collection Site: NOT SPECIFIED

ANABOLIC STEROID PANEL II

ANABOLIC STEROIDS Magativa 1.2 . ng/mL DHEA 16.6 TESTOSTERONZ ng/mL ng/mL EPITESTOSTERONE 3.3 T/E RATIO 3.0

T/Z Ratio is considered positive at a value greater than 8. The following

anabolic agents were tested:

Bolasterone Methandienone Boldenone enorelogin Clembaterol Mandrolone

Norethandrolone/Ethylestrenol Clostebol

Danazel Oxandrolone Oxymesterone Dromostanolone Oxymetholone Dehydrochloromethyltestosterome Stanozolol Dihydrotestosterone Stenbolona Fluoxymesterone Trembolone Formebolone

Probenecid (masking agent) Furazabol Methyltestosterone

Masterolone

Methenolone Methandriol

and related compounds

Accession #: Y2733151

· .

BATTE: [

Quest Diagnostics Incorporated 7470 Mission Valley Road Sam Diego, CA 90108 819.588.3000

-BALCO (14055) BALCO LABORATORY ATTN: VICTOR CONTE 1510 GALSRETE RD BURLINGAME, CA FABIG

Donor Name ID . 100401 Accession #: Y2893088 Donor IC/SSM: NOT SMECIFIED Other ID: NS . Concest Mame: Specimen Type: URINE

Date Time Collecter: 10:13:200: 89:00 Received: 10:23:000: 10:302M Reposted: 10/25/3981 03:30 SM Status: / Final Paport Raquast Type: Not Epacified

Emoloves: NS

Collection Site: NOT SPECIFIED

ANABOLIC STEROID PANEL II

ANABOLIC STEROIDS

TESTOSTERONE EFITESTOSTERONE NOT DETECTED

Magaziva

ոց/տև 19.0 ag. al 0.2 n ::/ mL

T/E Ratio is considered positive at a value greater than 8. The following

anabolic agents were tested:

Eclastatona Eoldenone Cleabutecol Clostabol Danazol

Dromostanologe Dehydrochloromathylcastosterona Dihydrotestosterone

Fluoxymeanerone Formsbolone Furazapol

Masterplone Methaniriol

and related compounds

Mathandienone Mibolerone Nandrolons

Norethandrolone/Ethylestrenol

Oxandrolons Oxymesterone enclodsemyxO Stanozolol Stenbolone Tranboloma

Probeneoud (masking agent)

Mechyliesbosterone

Mechanologs

Accession #: Y2893085

•		

BATCK: I

`SALCO (14059) Quest Diagnostics Incorporated 7470 Mission Valley Foad San Diego, CA 92108 519.588.3900

BALCON LABORATORY ATTN: VICTOR JONIE 1520 GALBFERM AD BURLINGAME OF 94818

Donor Name/ID | 188414 Date Time Collected: 11/05 3981 Accession #: Y2920E85 Fedeived: 11/03/2001 11/4348 Dogos 15/88M. NOT SPECIFIED Papostad: . 11-14-2001 00:30 9M Other IC: Status: / Final Papert Contact Hame: Specimen Type: UFINE - Request Type: Not Specifies Employer: NS Collection Site: NOT SPECIFIED

ANABOLIC STEROID PANEL II

Negative AMABOLIC STEROIDS 17 πg/mL 15.3 TESTOSTERONE ng/ml EPITESTOSTERONE 8.ହ ng/mL T/E RATIO 2.0

\_\_\_\_\_

T/E Ratio is considered positive at a value greater than 8. The following

anabolic agents were tested:

Bolasterone Mechandienoue Mibelerona enonabioa Mandrolous Clambutacol Norethandrolone/Ethylestranol Clostebol enoicibnexO Danazol

Dromostanolone Daymesterone Oxymetholone Dehydrochlosomethyltestosterone Stanozolol Pihydrotestosterone Stenbolone Fluoxymesterone Tiembolome


Formebolone Furazabol Probeneoid (masking agent) Machyltascoscerone Mesterologe Mechenologe

Methandriol

and related compounds

Accession %: Y2920555

	,	•	ر		



10101 Renner Boulevard Lenexa, KS 66219

## For Customer Service, call 1-800-646-7788

```
Site #: 0100105395
                              Report: 1/1
                                                    Distribute to: .
      PATIENT: BONGS, BARRY CLIENT PATIENT ID: ?
                                                              ACCOUNT: J9R3
REF DR: UNKNOWN
      REQ NUMBER: 70146002-16
IO OR ROOM NO: UNKNOWN
PAGE DOB/AGE: Jul 24 1964/37 YEARS
      DOB/AGE: Jul 24 1964/3/ YEARS
SEX: M FASTING: YES HRS: 12
DATE/TIME COLL: NOV 08 2001 00:00
DATE RECEIVED: NOV 09 2001 06:50 AM
DATE COMPLETED: NOV 13 2001
DATE REPORTED: NOV 13 2001
      SEX: M
                                                              BALCO LASS
                                                              1520 GILBRETH ROAD
                                                              EURLINGAME, CA $4010
      REPORT STATUS:
                            FINAL REPORT
                                  IN RANGE OUT OF RANGE
                                                                       REFERENCE UNITS
RESULT NAME
SEND OUT TESTS PERFORMED AT:
AMERICAN MEDICAL LAB, INC
14225 NEWBROOK DRIVE
P. D. BOX 10841
CHANTILLY, VA 20153-0841
Free and Total Testosterone
Free and Total Testosterone
                                                                              9.5-29.7 pg/mL
Free Testosterone
                                 11 2
Total Tastosterone
                                 336
                                                                               240-950 ng/dL
% Free Tastosterone
                                 0.3
                                                                               0.2-0.7 %
SEND OUT TESTS PERFORMED AT: ARUP LABORATORIES
500 CHIPETA WAY
SALT LAKE CITY, UT 84108
IGF-1 (INSULIN-LIKE GROWTH I) FROZEN AT LABONE.
IGF-1 | INSULIN-LIKE GROWTH I)
                                                                         114-492 ng/mL
                                                              100
REFERENCE INTERVAL: IGF-1 [Insulin-Like Growth I]
                                                                FEMALE
                                         MALE
                                                          17-248 ng/mL
88-474 ng/mL
117-771 ng/mL
             2 mos-5 yrs
                                    17-248 ng/mL
             6-8 yrs
9-11 yrs
                                    88-474 ng/mL
                                  110-565 ng/mL
             12-15 yrs
16-24 yrs
                                                           261-1096 ng/mL
182-780 ng/mL
                                  202-957 ng/mL
182-780 ng/mL
                                                           114-492 ng/mL
                                  114-492 ng/mL
             25-39 yrs
                                                            90-360 ng/mL
             40-54 ÿrs
                                    90-360 ng/mL
             55 yrs and over
                                  71-290 ng/mL
                                                            71-290 ng/ml
             Values by Tanner Stage:
                                                                FEMALE
                                         MALE
             TANNER STAGE
                                                           128-470 ng/mL
                                  109-485 ng/mL
             I
I I
                                  174-512 ng/mL
230-818 ng/mL
385-775 ng/mL
                                                           186-695 ng/ml
                                                           292-883 ng/mL
             III
                                                           394-920 ng/mL
             ΙV
                                                           308-1138 ñg/mL
                                  402-839 ng/mL
                             - REPORT CONTINUED ON NEXT PAGE -
```

10101 Renner Boulevard Lenexa, KS 66219

For Customer Service, call 1-800-646-7788

Site #: 0100105395

Report: 1/1

Distribute to: .

PATIENT: BONDS, BARRY CLIENT PATIENT ID: ? RED NUMBER: 70146002-16

ACCOUNT: JORG REF DR: UNKNOWN

PAGE DOR ROOM NO: UNKNOWN
PAGE DOS/AGE: Jul 24 1964/37 YEARS
SEX: M FASTING: YES HRS: 12
DATE/TIME COLL: NOV 08 2001 06:00
DATE RECEIVED: NOV 09 2001 06:50 AM
DATE COMPLETED: NOV 13 2001
DATE REPORTED: NOV 13 2001
REPORT STATUS: FINAL REPORT

BALCO LABS 1520 GILBRETH ROAD BURLINGAME, CA 94010

RESULT NAME

IN RANGE

OUT OF RANGE

REFERENCE UNITS.

END OF REPORT FOR BONDS, BARRY



1010 Inner Boulevard Lenexa, KS 66219-9752 (800) 646-7788

now a part of Quert Diagnophics BARRY

CLIENT PATIENT ID: ?

REQ NUMBER: 70146002-16 ID OR ROOM NO: UNKNOWN

PAGE DOB/AGE: Jul 24 1964/37 YEARS

FASTING: YES HRS: 12

DATE/TIME COLL: Nov 08 2001 00:00

DATE RECEIVED: Nov 09 2001 06:50 AM DATE REPORTED:

Nov 13 2001 Nov 28 2006 DATE RE-SENT:

RESEND REPORT REPORT STATUS:

ACCOUNT: J9R3 REF DR: UNKNOWN

BRIAN GOLDMAN, MD 1520 GILBRETH ROAD BURLINGAME, CA 94010

IN RANGE OUT OF RANGE RESULT NAME REFERENCE BLOOD CHEMISTRY NO HEMOLYSIS DETECTED NO LIPEMIA DETECTED NO ICTERUS DETECTED SODIUM 140 136 - 146 MEQ/L 3.6 - 5.1 MEQ/L 4.4 POTASSIUM 98 - 109 MEQ/L 60 - 109 MG/DL 8.5 - 10.5 MG/DL 102 CHLORIDE GLUCOSE 75 CALCIUM 9.4 6 - 23 MG/DL 20 BUN 0.3 - 1.5 MG/DL 1.6 CREATININE 10 - 22 12.5 BUN/CREAT RATIO 0.2 - 1.3 MG/DL 0.5 TOTAL BILIRUBIN AST (SGOT) 67 10 - 45 U/L11 - 45 U/L ALT (SGPT) 177 40 - 115 U/L 6.3 - 7.8 G/DL 3.90 - 5.20 G/DL 79 ALKALINE PHOSPHATASE 7.5 TOTAL PROTEIN 4.3 ALBUMIN 1.8 - 3.5 G/DL 3.2 GLOBULIN 1 - 2.5 10 - 150 MG/DL 140 - 199 MG/DL A/G RATIO 1.3 TRIGLYCERIDES 222 CHOLESTEROL BORDERLINE HIGH CHOL 200 - 239 MG/DL HIGH CHOLESTEROL >= 240 MG/DL27 - 75 MG/DL HDL CHOLESTEROL 0 - 5 5.6 CHOL/HDL RATIO 0 - 129 MG/DL 161 LDL CHOLESTEROL, CALC 5 - 35 MG/DL 20 VLDL, CALCULATED 4.04 1.52 - 5.52LDL/HDL RATIO 21 - 30 MEQ/L 26 BICARBONATE HEMATOLOGY 15.4 14.0 - 18.0 G/DL HGB 44.0 - 54.0 % HCT 46.4 4.70 - 6.10 MILLION/MCL 5.70 RBC 83 - 103 FL 26.0 - 35.0 PG MCV 26.9 MCH 30.0 - 37.0 G/DL 33.2 MCHC 11.5 - 14.5 % 4.0 - 11.0 K/MCL 15.1 RDW 5.7 WBC 42 - 77 % 48 NEUTROPHILS 16 - 43 % 4 - 12 % 43 LYMPHOCYTES MONOCYTES 6 0 - 8 % 3 EOSINOPHILS 0 0 - 3 % BASOPHILS 130 - 400 K/MCL PLATELET COUNT 231 - REPORT CONTINUED ON NEXT PAGE -

MEDICARE #9004083 \* CLIA #17D0648226

LABONE\_00087

CONFIDENTIAL



1010 ... ... ner Boulevard Lenexa, KS 66219-9752 (800) 646-7788

now a part of the Nept Diagnostics BARRY

CLIENT PATIENT ID: ?

REQ NUMBER: 70146002-16 ID OR ROOM NO: UNKNOWN

PAGE DOB/AGE: Jul 24 1964/37 YEARS

2 SEX: M FASTING: YES HRS: 12

DATE/TIME COLL: Nov 08 2001 00:00

Nov 09 2001 06:50 AM DATE RECEIVED: Nov 13 2001 Nov 28 2006 DATE REPORTED:

DATE RE-SENT: REPORT STATUS:

RESEND REPORT

BRIAN GOLDMAN, MD 1520 GILBRETH ROAD BURLINGAME, CA 94010

ACCOUNT: J9R3

REF DR: UNKNOWN

RESULT NAME OUT OF RANGE IN RANGE REFERENCE UNITS \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\* SEND OUT TESTS PERFORMED AT: QUEST DIAGNOSTICS AMD 14225 NEWBROOK DRIVE 800-336-3718 NICHOLS INSTITUTE CHANTILLY, VA 20153 Free and Total Testosterone Free and Total Testosterone Free Testosterone 11.2 9.5-29.7 pg/mL 240-980 ng/dL Total Testosterone 336 0.3 0.2-0.7 % % Free Testosterone SEND OUT TESTS PERFORMED AT: ARUP LABORATORIES 500 CHIPETA WAY 800-522-2787 SALT LAKE CITY, UT 84108 IGF-1 (INSULIN-LIKE GROWTH I) FROZEN AT LABONE. IGF-1 (INSULIN-LIKE GROWTH I) 100 . 114-492 ng/mL REFERENCE INTERVAL: IGF-1 (Insulin-Like Growth I) MALE FEMALE AGE 2 mos-5 yrs 17-248 ng/mL 17-248 ng/mL 88-474 ng/mL 88-474 ng/mL 6-8 yrs 9-11 yrs 12-15 yrs 117-771 ng/mL 110-565 ng/mL 202-957 ng/mL 261-1096 ng/mL 182-780 ng/mL 16-24 yrs 182-780 ng/mL 25-39 yrs 114-492 ng/mL 114-492 ng/mL 40-54 yrs 90-360 ng/mL 90-360 ng/mL 55 yrs and over 71-290 ng/mL 71-290 ng/mL Values by Tanner Stage: TANNER STAGE MALE FEMALE 109-485 ng/mL 128-470 ng/mL Ι 174-512 ng/mL ΙI '186-695 ng/mL 230-818 ng/mL 292-883 ng/mL III 396-776 ng/mL 394-920 ng/mL IV CONFIDENTIAL 402-839 ng/mL 308-1138 ng/mL V

MEDICARE #9004083 \* CLIA #17D0648226

LABONE\_00088

	<b>)</b>	



1010. ...ner Boulevard Lenexa, KS 66219-9752 (800) 646-7788

now a part of the Diagnostics BARRY

CLIENT PATIENT ID: ?

ACCOUNT: J9R3 REF DR: GOLDMAN

REQ NUMBER: 69552984-16

ID OR ROOM NO: UNKNOWN

PAGE DOB/AGE: Jul 24 1964/37 YEARS

1 SEX: M FASTING: YES HRS: 09 DATE/TIME COLL: Dec 03 2001 01:00 P

DATE/TIME COLL: Dec 03 2001 01:00 PM DATE RECEIVED: Dec 05 2001 08:30 AM

DATE REPORTED: Dec 05 2001
DATE RE-SENT: Nov 28 2006

BRIAN GOLDMAN, MD 1520 GILBRETH ROAD BURLINGAME, CA 94010

REPORT STATUS: RESEND REPORT

RESULT NAME	IN RANGE	OUT OF RANGE	REFERENCE UNITS
BLOOD CHEMISTRY NO HEMOLYSIS DETECTED NO LIPEMIA DETECTED NO ICTERUS DETECTED			
SODIUM	140		136 - 146 MEQ/L
POTASSIUM	4.5		3.6 - 5.1 MEQ/L
CHLORIDE	102		98 - 109 MEQ/L
GLUCOSE	95		60 - 109 MG/DL
CALCIUM	9.3		8.5 - 10.5 MG/DL
BUN	17		6 - 23 MG/DL
CREATININE		1.6	0.3 - 1.5 MG/DL
BUN/CREAT RATIO	10.6		10 - 22
TOTAL BILIRUBIN	0.6		0.2 - 1.3 MG/DL
AST (SGOT)		74	10 - 45 U/L
ALT (SGPT)	0.4	165	11 - 45 U/L
ALKALINE PHOSPHATASE	84		40 - 115 U/L
TOTAL PROTEIN	7.1		6.3 - 7.8 G/DL
ALBUMIN	4.1		3.90 - 5.20 G/DL
GLOBULIN	3.0		1.8 - 3.5 G/DL
A/G RATIO	1.4		1 - 2.5
BICARBONATE	. 28		21 - 30 MEQ/L
			•

END OF REPORT FOR BONDS, BARRY

CONFIDENTIAL

·	C		
	·		
			·



1010. nner Boulevard Lenexa, KS 66219-9752 (800) 646-7788

BARRY

now a partient: Dismosics BARR CLIENT PATIENT ID: ?

ACCOUNT: J9R3 REF DR: GOLDMAN

REQ NUMBER: 70145995-16

ID OR ROOM NO: UNKNOWN

PAGE DOB/AGE: Jul 24 1964/37 YEARS

FASTING: YES 1 SEX: M HRS:

DATE/TIME COLL: Jan 08 2002 10:00 AM

DATE RECEIVED: Jan 10 2002 09:05 AM DATE REPORTED: Jan 10 2002 DATE RE-SENT: Nov 28 2006

REPORT STATUS: RESEND REPORT BRIAN GOLDMAN, MD 1520 GILBRETH ROAD BURLINGAME, CA 94010

RESULT NAME	IN RANGE	OUT OF RANGE	REFERENCE UNITS
BLOOD CHEMISTRY			
NO HEMOLYSIS DETECTED			
NO LIPEMIA DETECTED			
NO ICTERUS DETECTED			
SODIUM	138		136 - 146 MEQ/L
POTASSIUM	4.4		3.6 - 5.1 MEQ/L
CHLORIDE	104		98 - 109 MEQ/L
GLUCOSE	97		60 - 109  MG/DL
CALCIUM	8.7		8.5 - 10.5 MG/DL
BUN		28	6 - 23 MG/DL
CREATININE		1.8	0.3 - 1.5 MG/DL
BUN/CREAT RATIO	15.6		10 - 22
TOTAL BILIRUBIN	0.6		0.2 - 1.3 MG/DL
AST (SGOT)	34		10 - 45 U/L
ALT (SGPT)	37		11 - 45 U/L
ALKALINE PHOSPHATASE	75		40 - 115 U/L
TOTAL PROTEIN	6.7		6.3 - 7.8 G/DL
ALBUMIN	4.0		3.90 - 5.20 G/DL
GLOBULIN	2.7		1.8 - 3.5 G/DL
A/G RATIO	1.5		1 - 2.5
BICARBONATE	25		21 - 30 MEQ/L

END OF REPORT FOR BONDS, BARRY

CONFIDENTIAL

.

.



# St. Joseph's Hospital and Medical Center

#### LABORATORY REPORT



350 WEST THOMAS ROAD Phoenix, AZ 85013 Phone: (602)406-3410

MR : (0000)0104-82-47 ACCT: 75037069 NAME: BONDS, BARRY

02/25/02 0500 ADMIT: 02/16/02

AGE : 37 YRS SEX : M LABO LOC: ROOM : PHYSICIAN: REFERRED OUT PT

### HEMATOLOGY

DATE:	02/24/02
TIME:	1328

		· · · · · · · · · · · · · · · · · · ·	REFERENCE	UNIT
	COMPLETE BLOOD COUNT	T		
in.	PLATELET	305	150-450	TH/UL
1	WBC	7.6	3.6-11.1	TH/UL
	RBC	5.44	4.27-5.49	MIL/UL
	HEMOGLOBIN	15.2	12.9-16.1	
	HEMATOCRIT	45.6	37.7+46.5	&
	MCV	84	79-95	FL
	MCH	27.9L	28.0-32.0	PG
ø	MCHC	33.3	32.0-36.0	GM/DL
3	RDW	14.5	11.5-14.5	UNITS
	POLYS % (AUTO)	52.5	46.0-65.0	8
	LYMPHS % (AUTO)	39.1H	25.0-35.0	*
	MONO & (AUTO)	5.9	1.0-10.0	8
	EOS % (AUTO)	2.0	0.0-5.0	8
	BASOS & (AUTO)	0.5	0.0-1.0	8
	POLYS ABS	04.0	02.0-08.0	TH/OL
	LYMPHS ABS	3.0	1.5-4.0	TH/UL
-	MONOS ABS	0.4	0.1-2.0	TH/UL
3	EOS ABS	0.2	0.0-0.7	TH/UL
	BASOS ABS	0.0	0.0-0.2	TH/UL
	SLIDE REVIEWED	NONE		

### CHEMISTRY

	DATE: TIME:	02/24/02 1328		
			REFERENCE	UNIT
تحملت	CHEMISTRY PANELS			
	SODIUM	140	134-144	MEQ/L
	POTASSIUM	4.2	3.6-5.1	MEQ/L
	CHLORIDE	102	101-111	MEQ/L
	CO2	27	22-32	MEQ/L
أنس	BUN	21H	8-20	MG/DL
ل	CREATININE	1.8H	0.7-1.2	MG/DL
	GLUCOSE	84	74-118	MG/DL
	ANION GAP	11	7-15	
	CALCIUM	9.6	8.9-10.3	MG/DL
	CHOLESTEROL	211H	50-200	MG/DL
	TRIGLYCERIDES	154	20-190	MG/DL
	HDL CHOLESTEROL	19L	29-71	MG/DL

1 (CONTINUED.

PAGE

L = Low, H = High

LABORATORY DIRECTORS

DELIVER TO: REFERRED OUT PT

ROY IAN DAVIS, M.D. MEDICAL DIRECTOR CHAIRMAN-DEPARTMENT OF PATHOLOGY

E. SMITH COLLUM, M.D. DIRECTOR CLINICAL LABORATORY

SERVICES

MR-48C (10/98)

SFG (S.C.) 0823



# St. Joseph's Hospital and Medical Center

### CHW

350 WEST THOMAS ROAD Phoenix, AZ 85013 Phone: (602)406-3410

02/25/02 0500 ADMIT: 02/16/02

#### LABORATORY REPORT

MR : (0000)0104-82-47

ACCT: 75037069 NAME: BONDS, BARRY

AGE : 37 YRS LOC : LABO

SEX ROOM :

PHYSICIAN: REFERRED OUT PT

### CHEMISTRY

HDL CHOLESTEROL (Initial -- Current)

DECREASED RISK >35 INCREASED RISK <35

> DATE: 02/24/02 1328 TIME:

REPERENCE

0-130

UNIT

MG/DL

CHEMISTRY PANELS

LDL-CALCULATED

LDL-CALCULATED (Initial -- Current)

< 130 DESIRABLE BORDERLINE 130-160 > 160 HIGH

CANCELLED TEST SUMMARY

TIME

CANCELLED TEST

ORDER DATE

REASON

COMPREHENSIVE METABOLIC PANEL 24FEB02 1328 Test ordered in error.

H = High

PAGE 2 END OF REPORT

DELIVER TO: REFERRED OUT PT LABORATORY DIRECTORS E. SMITH COLLUM, M.D.

ROY IAN DAVIS, M.D. MEDICAL DIRECTOR CHAIRMAN-DEPARTMENT OF PATHOLOGY

DIRECTOR

CLINICAL LABORATORY

SERVICES

MR-48C (10/98)

SFG (S.C.) 0824



ner Boulevard Lenexa, KS 66219-9752 (800) 646-7788

now a participation in a participation by the company of the compa BARRY

REQ NUMBER: 70145977-16

ID OR ROOM NO: UNKNOWN

PAGE DOB/AGE: Jul 24 1964/37 YEARS

1 SEX: M FASTING: YES HRS:

DATE/TIME COLL: Apr 12 2002 10:00 AM

Apr 15 2002 06:05 AM DATE RECEIVED: Apr 15 2002 Nov 28 2006 DATE REPORTED:

DATE RE-SENT: REPORT STATUS: RESEND REPORT REF DR: UNKNOWN

ACCOUNT: J9R3

BRIAN GOLDMAN, MD 1520 GILBRETH ROAD BURLINGAME, CA 94010

RESULT NAME	IN RANGE	OUT OF RANGE	REFERENCE	UNITS
BLOOD CHEMISTRY				
NO HEMOLYSIS DETECTED				
NO LIPEMIA DETECTED				i
NO ICTERUS DETECTED				
SODIUM	139		136 - 146	MEO/I.
POTASSIUM	4.1		3.6 - 5.1	MEO/I.
CHLORIDE	105		98 - 109	MEO/I.
SODIUM POTASSIUM CHLORIDE GLUCOSE CALCIUM	104		98 - 109 60 - 109	MG/DI.
CALCIUM	9.1		8.5 - 10.5	MG/DL
BUN		26	6 - 23	MG/DL
CREATININE		1.7	6 - 23 0.3 - 1.5	MG/DL
BUN/CREAT RATIO	15.3		10 - 22	,
TOTAL BILIRUBIN	0.3		10 - 22 0.2 - 1.3	MG/DL
AST (SGOT)		51	10 - 45	U/L
ALT (SGPT)		57	77 45	TY / T
ALKALINE PHOSPHATASE	84		40 - 115	U/L
TOTAL PROTEIN	6.5		6.3 - 7.8	G/DL
ALBUMIN		3.8	3.90 - 5.20	G/DL
ALBUMIN GLOBULIN A/G RATIO BICARBONATE	2.7		1.8 ~ 3.5	G/DL
A/G RATIO	1.4		1 - 2.5	
BICARBONATE	1.4 23		21 - 30	MEQ/L
HEMATOLOGY				
	14.6		14.0 - 18.0	G/DL
HCT	49.1		44.0 - 54.0	-/ 署
RBC	5.40	•	44.0 - 54.0 4.70 - 6.10 83 - 103 26.0 - 35.0	MILLION/MCL
MCV	91		83 - 103	FL
MCH	27.1		26.0 - 35.0	PG
MCHC		29.7	30.0 - 37.0	G/DL
RDW		16.4	11.5 - 14.5	8
WBC	7.6		4.0 - 11.0	
NEUTROPHILS	60		42 - 77	
LYMPHOCYTES	36		16 - 43	
MONOCYTES		3	4 - 12	
EOSINOPHILS	1		0 - 8	8
BASOPHILS	1		0 - 8 0 - 3 130 - 400	8
PLATELET COUNT	239		130 - 400	K/MCL
REMARKS: RESULTS MAY BE AFF	ECTED BY SP	ECIMEN AGE.		
				1

END OF REPORT FOR BONDS, BARRY

CONFIDENTIAL

. •

41125218 AREA/ROUTE/STOP: XXXXXXXX

BALCO LABORATORY ATTN: VICTOR CONTE 1520 GALBRETH RD BURLINGAME, CA 94010





Quest Diagnostics

PARTICIPANT NAME	PARTICIPANT ID	ROCM NO	AGE SER PHYSICIAN	
100545	ILAS REF. #	COLLECTION DATE & TIME	LOS-IN-DATE   REPORT DATE	14 TIME
1 0100545 069048A		12202002	12232002   12262302	2:50 PM

REMARKS Client Site Location:
FEASON FOR TEST: UNRUNOWN
DONGER ID VERIFIED:

		1507	RES	5UL7	UNTS	REFERENCE	SITE
REPORT STATUS	FINAL	7237	EDNAR M	OUT OF RANGE	UIT 1 3	RANGE	SITE C0DE
REPORT FO	₽ <b>F</b> , :	ATTN: 1520	LABORATOR VICTOR ( GALERETH R MGAME, CA	<b>5</b> - C	218		
Tests Orde	ered: 3829	)2N (STERCI	D PANEL 2;				
Anabolic A	gents						
ANAEOLIC	AGENTS		Megative				
Masking Ag	gents						
MASKING A	GENTS.	:	 Megative 				
Drug Class	Tested						
anabo	ilic Agents	; :					
Clo (De Dib Eth Met Met Met Nor Sta And	estebol Metehydrochlor hydrochlor hydrotestos hylestrenol metelite, E thandrosten mabolite, M mandrostend or Metaboli hicotendiol	abolite, De fomethyltes terone, Dro Norethand formebolone Metabolone Methenolone dibolerone dione/Norandte, Oxymes etabolite, T/E	nazol &/d tosterone) mostanold rolone Met Metaboli: lite, Meta abolite, li &/or Meta terone, C: testostero	metabolic Metabolic ne %/or Hetabolic e, Fursian endienone ethandrich bolite, Metabolic ymetholore ne/Andros	te, stabolite, Tluoxymesterone ci Metabolite, (Dianabol, &/or stnyltestostero ne/ te, Oxandrolon Metabolite,	n e e	
<u>Ma</u> ski	.ng Agents: >> REPORT	CONTINUEL	   Den beken fi 	GE <<			स्. ख्ट्राम् -

41125218 AREA/ROUTE/STOP: MXXXXXXX

BALCO LABORATORY ATTN: VICTOR CONTE 1520 GALBRETH RD BURLINGAME, CA 94010





Quest
Diagnostics
continued resear

١.				,					
$^{\sim}$	PARTICIPANT NAME		PARTICIPANT ID	ROOM	NO AGE SE	H PHYSICIAN			۰,
	100545 .								
₽	AGE REQUISITION NO AC	CCESSION NO.	LAS REF #	COLLECTION DATE & TI	ME LOG-IN-	DATE REPO	DET DATE	& TIME	_
	2 0100545	069048A		12202002	1223	2002 12:	262002	2:50PM	ļ
	DEMASKS: 11 - 0 -	Sire Joces							

REMARKS Ditent Site Location: REASON FOR TEST: UNKNOWN DONGE, ID VERIFIED:

REPORT STATUS		TEST		SULT	UNITS	REFERENCE	SITE
ELFORT STATUS	FINAL	1231	IN RANGE	CUT OF RANGE	Units	RANGE	SITE CODE
				4 1			
			,				
REFORT FO	ND -	BALCO	LABORATOR	Y - 41125	218		
1.021 0111 111			VICTOR (				
			GALBRETH B				
		EURLI.	NGAME, CA	94010			
			,				
			-				
Drug Class	Tested						
Pro	benecid, E	pitestoste.	‡one (> 20	}o wa\wr) }			
	CERTIFYING	SCIENTIST	CAROL PE	INNOYER			
					CORCAGIC MOVI	COLOCY INDODATE	- · ·
SPECIMEN R	ECEIVED AN	D PROCESSE	o IN LHE'S	AN DIEGO	FORENSIC TOXIO	COLOGY LABORATOR	1.75
LAE:	Quest Diag	nesties	: 				
		on Valley I	 Road				
	San Diego	CA 92108					
	own trigo	31. 32.200					
		;	> END CE	PEPORT <			
				İ			
				-			
				ĺ			
			ļ				
			ĺ				
				İ			
				i i			
				,			
				i			
			I.				
			i				

41125218 AREA/ROUTE/STOP: XXXXXXXX

EALCO LABORATORY
ATTN: VICTOR CONTE
1520 GILBRETH RD
BURLINGAME, CA 94010





REMARKS Client Site Location:

REASON FOR TEST: NOT GIVEN

DONOR ID VERIFIED:

REPORT STATUS		TEST	RES	BULT	i UNITS	REFERENCE	SITE
REPORT STATUS	FINAL	1231	IN RANGE	OUT OF RANGE	0,41,5	RANGE	CODE
•			,				
DIES DE ES	· F.	537.00	* * * * * * * * * * * * * * * * * * * *	 {Y - 41125	510		
REPORT FO	DR:	ATTN:			1210		
			FILERETH S	1.			
			,				
		SUPLIF	GAME, CA	94010			
Tests Orde	red: 3828	99M (STERCIE	1 W/NIT)				
				• .	_	,	
Integrity	Checks				Acceptable	Range	
CREATININ	i E	4	15.3 ma/a	(t. 7 8)	>20 m	g /dī.	
NITRITES		Ŋ	egative			·9. ·	
pH		_	7.1		4.5	-9.0	
<b>P</b>							
Anabolic A	dents						
	. 9 - 11 - 10						
ANABOLIC	AGENTS	N	egative				
		_	3				
Masking Ag	ents						
MASKING A	GENTS	Ŀ	egative	:			
Drug Class	Tested						
odsnA	lic Agents	s:					
					te, Clembutero	1,	
		abolite, Da					
		cmethyltest					
Dih	ydrotestos	terone, Dro	mostanold	ne 4/or M	letabolite,		
					Fluoxymesteron		
					bol Metabolite	,	
					(Dianabol,		
Met	handrosten	clone) Meta	colite, N	ethandrid	1 &/or		
					ethyl testoster	one	
Met	abolita, M	Libolerone N	etabolite	, Nandrol	one/		
					ite, Oxandrolo	u e	
					e Metabolite,		
		tabolite, T			tendione/		,
	>> PEPORT	CONTINUED o	N NEXT PA	GE <<			. }

41125218 AREA/ROUTE/STOP: MXXXXXX

BALCO LABORATORY
ATTN: VICTOR CONTE
1520 GILERETH RD
BURLIMGAME, CA 94010





PARTICIPANT NAME	PARTICIPANT IO	HOOM NO. AGE	SEX PHYS	SICIAN	<del></del>
100552	100552				
PAGE REQUISITION NO ACCESSION NO.   LAE	REF # COLLECTION DA	TE & TIME LOG	-IN-DATE	REPORT DATE	à TIME
2 9006665 008194H	02062003	03	152003	02202003	9:27AM

REMARKS Client Site Location:
REASON FOR TEST: NOT GIVEN
DONCE ID VERIFIED:

REPORT STATUS		TEST	RE	SULT	UNITS	REFERENCE RANGE	SiTE
CEPORT STATUS	FINAL	1221	IN RANGE	OUT OF RANGE		RANGE	SITE
REPORT FO	ne ·	EALCO	LABORATO	Y - 41125218			
1.1110111		ATTN:					
			ILBRETH !	k			
			GAME, CA				
Drug Class	Tested		: : :				
Anc	irostendiol	L/DHEA (T/E	Ratio > (	), Trenbolone	: Metabolite		
Maski	ng Agents:		e Holley e				
		Epitestoste:	one (> 20	D ng/mL)			
	.20110020, 2						
	CERTIFYING	SCIENTIST:	MOHAMMAI	GHAZIZADEH			
PECIMEN R	ECEIVED AN	D PROCESSED	IN THE I	AS VEGAS DHHS	CERTIFIED	LABOFATORY.	
LAE:	Onest Diac	nostics Ind	-Las Veds	s			
	4230 South						
	Las Vegas						
		*	> END OF	PEPORT <			
				11 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1			
			•				
			: :				
							:
				,			
				,1			

Chandler Regional Laboratory \*\*LIVE\*\* RUN DATE: 02/26/03 PAGE 1 RUN TIME: 1113 Specimen Inquiry RUN USER: LAB.BEA ACCT #: V1518087 U #: FIENT: SFG BONDS, BARRY LOC LAB AGE/SX: 38/M ROOM: REG: 02/23/03 REG DR: UNKNOWN, D DOB: 07/24/64 BED: DIS: STATUS: REG REF TLOC: STATUS: COMP REQ #: 01021891 SPEC #: 0223:H00152R COLL: 02/23/03-1340 RECD: 02/23/03-1548 SUBM DR: UNKNOWN, D 02/23/03-1548 OTHR DR: ENTERED: ORDERED: CBC, MAN DIFF Flag Result Reference Test CBC WRC 7.5 (4.8-10.8) 10x3/ul 5.51 (4.70-6.10) 10x6/ul RBC 14.6 (13.5-18.0) gm/dl HGB HCT 43.2 (40.0-52.0) % 78.3 (80.0-99.0) fl MCV (27.0-34.0) pg MCH 26.5 33.8 (32.0-37.0) gm/dl MCHC 15.1 (11.5-18.0) 🕏 RDW 355 (130-400) 10x3/ul PLT (10.0-55.0) % 56.2 \*LYMPH 7.3 (0.0-15.0) % **&MONOS** (35.0-80.0) % 35,2 \*GRAN 0.9 (0.0-11.0) % %EOS (0.0-3.0) \$ 0.4 \*BASO 4.2 (0.8-5.0) 10x3/ul ABS LYMPH 0.5 (0,0-1.5) 10x3/ul ABS MONO 2.6 (1.4-12.0) 10x3/ul ABS GRAN (0.0-1.2) 10x3/ul 0.1 ABS EOS (0.0-0.3) 10x3/ul ABS BASO 0.0 MAN DÏFF (25-45) % 58 LYMPH (2-8) % 8 MONOS (45-75) % 30 POLY

ADEQ

BAND

PLT ESTIMATE

(0-5) %

(ADEQ)

# NSIC DRUG TESTING CUSTOD AND CONTROL FORM





51015032

1199 SPECIMEN ID NO

STEP 1: COMPLETED BY COLLECTOR OR EMPLOYER REPRESENT	ATIVE LAB ACCESSION NO.
A. Employer Name, Address, I.D. No.	B. MRO Name, Address, Phone and Fax No. विशेष के विश्वपारिकी ।
	AR MIKE MILLIAM TO
Pt 434 114	F T 80x 3x41
Company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the company of the compan	.5%4 64%40 - a - 00+ 4
型头面面 (1) 在14年(2)5年4月(82)40日(425年	The Market Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of
C. Donor SSN or Employee I.D. No. 45 3 2 5 9	
D. Donor Name: Last: Las	First: [ ] OF TOTAL FOR THE TOTAL FOR THE
E. Donor ID Verified: Photo ID Emp. Rep.	
F. Reason for Test: Pre-employment (1) Random (3) Re Return to Duty (6) Follow-up (23)	easonable Suspicion/Cause (5) Post-Accident (2) Promotion (22) Other (specify) (99)
G. Drug Tests to be Performed:	,——————————————————————————————————————
⊀ 1 for the to the total	
H. Collection Site Name: H. Collection Site Name: Col	lection Site Code:
Address:	Collector Phone No. 210 6 2 1969
City, State and Zip: AN - NAME (10)	Collector Fax No.: 416 6 1964
STEP 2: COMPLETED BY COLLECTOR	
Read specimen temperature within 4 minutes. Is temperature Specimen	
between 90° and 100° F? Yes No, Enter Remark Split	Single None Provided (Enter Remark) Observed (Enter Remark)
	Carried and Mark Community Community
STEP 3: Collector affixes bottle seal(s) to bottle(s). Collector dates seal(s). STEP 4: CHAIN OF CUSTODY - INITIATED BY COLLECTOR AND CO	
I ceruly may the spacimen given to me by the conor identified in the certification section on Coope at this logic was collected.	· · · · · · · · · · · · · · · · · · ·
X Mel Land 4,09 AM	SPECIMEN BOTTLE(S) RELEASED TO:
Signature of Collection	➤ Quest Diagnostics Courier ☐ FedEx
1466 1. C. WINESSY -121119	Airborne Other
(Print) Collector's Name (First. MI, Last)  Date (Mo /Ďay/Yr.)	Name of Delivery Service Transferring Specimen to Lab
AT LAB:  Signature of Accessioner	Primary Specimen Bottle Seal Intact  SPECIMEN BOTTLE(S) RELEASED TO:
Signature of Actualitiner	Yes
(Print) Accessioner's Name (First, MI, Last)  Date (Mo./Day/Yr.)	No, Enter Remark Below
STEP 5: COMPLETED BY MEDICAL REVIEW OFFICER (IF REQUIRED	
I have reviewed the aboratory results for the specimen identified by this form in accordance with applicate Negative Positive Session Test Not Performed Test Cancelled REMARKS	ole requirements. My determination/verification is:
	/ /
(PRINT) Medical Review Officer's Name (First, MI, Last)	Signature of Medical Review Officer Date (Mo. / Day / Yr.)
STEP 6: COMPLETED BY DONOR	
I certify that I previous my ushe specimen to the collector; that I have not adulterated it in any manner; ear numbers provided on this form and on the label affixed to each specimen bottle is correct.	ich specimen bottle used was sealed with a tamper-evident seal in my presence; and that the information and
X and Sa	2 Ry Donas 05/28/07
Signature of Donor	PRINT) Donor's Name (First, MI, Last)  Date (Mo./Day/Vr.)  Date of Birth
Daytime Phone No. (465) 972-163/ Evening Phone No. (	Date of Birth 129/69

REPRINT

COPY FROM CDT BOS - 51015032 40020341 AREA/ROUTE/STOP: XXXXXXX CDT

PO BOX 3847 LONG BEACH, CA 90803



PATIENT NAME PATIENT ID POOM NO AGE PHYSICIAN 2552259 PAGE | REQUISITION NO. ACCESSION NO. LAB REF. # COLLECTION DATE & TIME LOG-IN-DATE REPORT DATE 3 TIME 0085189 047425H 05282003 04:03PM 05292003 96012003 6:10AM REMARKS

Client Site Location: REASON FOR TEST: NOT SPECIFIED DOBOR ID VERIFIED: EMPLOYER REPRESENTATIVE

REPORT FOR:

CDT BOS - 51015032

PO 80X 3247

LONG BEACH, CA 90803

Tests Ordered: 39434N (BOS PROFILE I W/HIT)

Invegrity Checks

Acceptable Range

CRESTININE

286.3 mg/dL

⇒20 mg/di.

NITRITES

 $(2^{k})$ 

Negative 6.6

4.5-8.9

Anabblic Agents

ANABOLIC AGENTS

Negative

Masking Agents

MASKING AGENTS

Negative

Drug Class Tested

#### Anabolic Agents:

Bolasterone Metabolite, Boldenone Netabolite, Clenbuterol, Clostebol Metabolite, DHCMT
(Dehydrochloromethyltestosterone) Metabolite,
Dihydrotestosterone, Dromostanolone &/or Metabolite,
Ethylestrenol/Norethandrolone Metabolite, Fluoxymesterone
Metabolite, Formebolone Metabolite, Furazabol Metabolite,
Mesterolone &/or Metabolite, Methandienone (Dianabol,
Methandrostenolone) Metabolite, Methandriol &/or
Metabolite, Methenolone &/or Metabolite, Nethyltestosterone
Metabolite, Mibolerone Metabolite, Nandrolone/
Norandrostendione/Norandrostendiol Metabolite, Oxandrolone
&/or Metabolite, Oxymesterone, Oxymetholone Metabolite,

>> REPORT CONTINUED ON NEXT PAGE </


では、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、10mmのでは、1

51015032 AREA/ROUTE/STOP: XXXXXXX

CDT

PO BOX 3247 LONG BEACH, CA 90803

LOPY FROM CDT BUS



ALPALOI



PATIENT NAME PATIENT IC ROOM NO. AGE SEX PHYSICIAN 2552259 PAGE REQUISITION NO. | ACCESSION NO LAB REF. # COLLECTION DATE & TIME LOG-IN-DATE REPORT DATE 3 TIME 2085189 Ø47425H 05262003 04:03PM 05292003 06012003 6:10AM

REMARKS Client Site Location:

REASON FOR TEST: NOT SPECIFIED

DONOR ID VEKIFIED: EMPLOYER MEPRESENTATIVE

REPORT FOR:

CDT BOS - 51015032

FO BOX 3247

LUMG BEACH, CA 90803

Prug ulass Tested

Stanozolol Metabolite, Testosterone/Androstendione/ Androstendiol/DHEA (T/E Ratio ) 6), Trenbolone Metabolite

hasking Agents: Probenecid

CERTIFYING SCIENTIST: MOMAMMAD GHAZIZADEH

EPECIMEN RECEIVED AND PROCESSED IN THE LAS VEGAS DHMS CERTIFIED LABORATORY.

LHES

Quest Diagnostics Inc-Las Vegas 4236 South Burnham Las Vegas NV 891,19


>> END OF REPORT (<

Specimen Acc. # 047425H

Data File : D:\MSDCHEM\1\DATA\0530HP4\047425H.D

MS Integration Params: NA

Vial: 75 : 31 May 2003 5:16 am Operator: ds Acq On : GCMS # 12 Sample Inst Multiplr: 1.00 Misc




Data File : D:\MSDCHEM\1\DATA\0530HP4\047425H.D

Vial: 75 : 31 May 2003 5:16 am Operator: ds

Sample Inst : GCMS # 12 Misc Multiplr: 1.00

MS Integration Params: NA

Quant Method : (RTE Integrator)



Vial: 75

: GCMS # 12

Operator: ds

Multiplr: 1.00

Inst

Data File : D:\MSDCHEM\1\DATA\0530HP4\047425H.D


: 31 May 2003 5:16 am Aca On

Sample

Misc

MS Integration Params: NA

Quant Method: (RTE Integrator)



Vial: 75

Inst : GCMS # 12

Operator: ds

Multiplr: 1.00

Data File : D:\MSDCHEM\1\DATA\0530HP4\047425H.D


Acq On: 31 May 2003 5:16 am

Sample

Misc

MS Integration Params: NA

Quant Method : (RTE Integrator)



## Laboratory Report

Acc. # 047425H Spec. I.D. # 0085189 Donor I.D. 2552259

CERTIFYING SCIENTIST: MOMMMHAD GHAZIZADEH  >> REPORT CONTINUED ON MEXT PAGE ((	bolasterone Nelabolita, Boldanona Hetabolita, Clant Clostebol Nelabolita, DMCNT  The Hydrockiorana Dyllasios tanona Nelabolita, Dibylasios tarona) Nelabolita, Boldanona Relabolita, Clant Clastebol Nelabolita, Dronostanolona Rora Hetabolita, Bibylasi fenol Negrethandrojen Nelabolita, Formabolona Ralabolita, Formabolina Ralabolita, Formabolona Ralabolita, Hetaholita, Formabolona Ralabolita, Hetaholita, Hetabolita, Dynastarona Nelabolita, Dynastarona, Oxysalholona  Nelabolita, Dynastarona, Oxysalholona, Nelabolita, Dynastarona, Oxysalholona, Nelabolita, Dynastarona, Oxysalholona, Nelabolita, Dynastarona, Oxysalholona, Nelabolita, Dynastarona, Oxysalholona, Nelabolita, Dynastarona, Oxysalholona, Nelabolita, Dynastarona, Oxysalholona, Nelabolita, Dynastarona, Oxysalholona, Nelabolita, Dynastarona, Oxysalholona, Nelabolita, Dynastarona, Oxysalholona, Nelabolita, Dynastarona, Oxysalholona, Nelabolita, Dynastarona, Oxysalholona, Nelabolita, Dynastarona, Oxysalholona, Nelabolita, Dynastarona, Oxysalholona, Nelabolita, Dynastarona, Oxysalholona, Nelabolita, Dynastarona, Oxysalholona, Nelabolita, Dynastarona, Dynastarona, Dynastarona, Dynastarona, Dynastarona, Dynastarona, Dynastarona, Dynastaron	Drug Class Tested	MASKING AGENTS MAG	5	ents	CREATININE 286	FINAL  1815 Ordered: 39434N (BUS PROFILE   MZKII)	2552259  1 0085189 047425H CITENT SITE LOCATION: REASON FOR TEST; NOT SPECIFIED BUNOR ID VEHIFIED: EMPLOYER REPRESENTATIVE	PO 00X 3247 LONG BEACH, CA 90803	SIBTSB32 AREKAROUTE/STOP: XXXXXXX
	Ita, Clanbularot,  Ita, Malabolita,  abol Malabolita,  a [Dianabol],  b [A]  Relabolita,  Italia, Oxandrolapa  itandlona,  planabolita,  planabolita,  planabolita,		Regalive	Negalive	4.5-8.9	Accaptable Range 286.3 mg/dL >20 mg/dL		03PK 05292003 65312003 6,44PK		
				·						

#### DOCUMENTATION PACKAGE COVER SHEET

Attached is a summary and copies of laboratory documents related to the analysis of Donor ID # 2552259, Specimen ID# 0085189 with accession number 047425H. The following 26 pages are true and accurate copies of the original documents that were generated during the normal course of business by Quest Diagnostics Incorporated. The original documents were generated at or near the time of each process.

The specimen (047425H) screened negative for steroids by GC/MS. The validity of the specimen was assessed by pH, creatinine and nitrates and was determined to be acceptable. Following review of the analytical data, and chain of custody documentation, a negative result was reported.

Documentation Package Reviewed by:

Victor Uralets, Ph.D. Signature

Technical Director Date

Title

Title

## **Table of Contents**

- General Overview of Laboratory Procedures 1.
- External Chain of Custody Form 2.
- 3. Pull List
- Screening Aliquot Chain of Custody 4.
- Screening Test Results 5.
- Laboratory Internal Chain of Custody (Worklist TXHP4, Steroids) 6.
- GC/MS Autotune 7.
- Steroid Positive Control 8.
- 9. Steroid Negative Control
- Steroid Water Control 10.
- Specimen Acc. # 047425H 11.
- Laboratory Report, Specimen Acc. # 047425H Certifying Scientist Resume 12.
- 13.
- Responsible Person Resume 14.

General Overview of Laboratory Procedures

#### GENERAL OVERVIEW OF LABORATORY PROCEDURES

#### Specimen Receipt

The laboratory acknowledges receipt of the specimen(s), verifies ID, and verifies that there is no evidence of tampering by examining the tamper-evident bag and specimen security seal. The external Custody and Control form (CCF) is completed and the internal laboratory Chain of Custody (COC) is initiated. All specimen and subsequent aliquot handling is carefully documented via internal COC.

#### Order Entry/Log-In

Client account number, specimen identification number, donor identification and testing information are logged into the specimen tracking computer system. A unique accession number is assigned to the specimen and an accession barcode label is affixed to the specimen container and accompanying CCF.

#### Aliquot for Screening Test

The specimen container is opened (breaking the seal) and a small portion of the sample is removed for the initial screening tests. The aliquot is transferred to the testing laboratory and the original specimen is placed in temporary secured storage. The handling of the specimen and the aliquot is documented on internal chain of custody form (CCF).

#### Specimen Validity Test

In order to assess the validity of specimens, the laboratory conducts tests for pH, creatinine and nitrates using enzyme immunoassay procedures on Olympus analyzers. Specific gravity testing is performed on all specimens that have a creatinine concentration that is less than 20 mg/dL. If specimen adulteration is suspected, the laboratory performs a confirmation test on the specimen. The confirmation test is performed on a second aliquot of the specimen that is obtained from the original specimen container.

#### Anabolic Steroid Screening Test

The specimen aliquot(s) along with calibration standard and controls are extracted for anabolic agents GC/MS screening. Procedure includes enzymatic hydrolysis of steroid conjugates, solid phase extraction of free steroids and their derivatization. The final extract is separated by capillary gas chromatography. Target components, anabolic steroids and/or their metabolites, are detected and identified by mass spectrometry.

#### Verification

The specimen identification number on the tamper evident seal is inspected a second time and verified as accurate.

#### Confirmation Test for Steroids

If the initial test result is positive, a second aliquot, obtained from the original specimen container, is tested by gas chromatography/ mass spectrometry. Confirmation procedures are specific for each individual steroid. If specimen was screened positive for multiple steroids, confirmation will be set up for each of them.

#### Certification

All data goes through a two-tier review process: initial review and certification. During the initial review process, the analyst reviews all analytical data. During the certification process, a certifying scientist reviews all analytical data and evaluates all documentation for acceptability and adherence to laboratory standard operating procedures.

gnostics Inc.	F. Reason for Test: Pre-employment (1) Random (3) Reason ble Suspicion/Cause (5) Post-Accident (2) Promotion (22)  Return to Duty (6) Follow-up (23) Other (specify) (99)	
Jest Dia	G. Drug Tests to be Performed:	
led fol	ok 39434N EDS PROFILE I W/NIT	
mostics Incorporal	H. Collection Site Name:   H. Collection Site Name:   Address:  City, State and Zip, AN FIGHUSCO, CA  Collector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No: COLLector Fax No:	-
of Quest Drag	Adcress: Collector Phone No. 5/0.652.896/ City, State and Zip AN PHANCECO, CA Collector Fax No.: 510.653.84	
narks (	STEP 2: COMPLETED BY COLLECTOR	
rade	Read specimen temperature within 4 minutes. Is temperature   Specimen Collection:	
ě	between 90° and 100° F? 💢 Yes 🗌 No, Enter Remark 💹 Split 🔲 Single 🗌 None Provided (Enter Remark) 💆 Observed (Enter Re	mark)
rks a	REMARKS /	
	STEP 3: Collector affixes bottle seal(s) to bottle(s). Collector dates seal(s). Donor initials seal(s). Donor completes STEP 6 on copy 2.  STEP 4: CHAIN OF CUSTODY - INITIATED BY COLLECTOR AND COMPLETED BY LABORATORY	
8	I certify the your specimen given tomp by the principal or identified in the gerulication section on Copy of this form was collected, labeled, seeled, and released to the Delivery Service noted in accordance with applicable requirements.	
Onest	X / All - Amely 1 4: Ob Am SPECIMEN BOTTLE(S) RELEASED TO:	
ciated	Signaph of Collection  Time of Collection  Quest Diagnostics Courier  FedEx	
d an asso	Airborne    Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne   Airborne	<b>y</b>
ed fogo an	RECEIVED X Elula   Primary Specimen Bottle (S) RELEASED Bottle Seal Intact	TO:
RUCIA	Signature of Accessioner  Yes	
į	(Print) Accessioner's Name (First, MI, Last)  Date (Mo./Day/Yr.)  No, Enter Remark Below	
\$10C	TEP 5: COMPLETED BY MEDICAL REVIEW OFFICER (IF REQUIRED)	
se Diagno	I here reviewed the laboratory results for the specimen identified by this form in accordance with applicable requirements. My determination/verification is:  Negative Positive Test Not Performed Test Cancelled REMARKS	
9		
3	[PRINT] Medical Review Officer's Name (First, MI, Lest) Signature of Medical Review Officer Date [Mo + Day / Yr.]	1

Pull List

PAGE

1

05/29/2003

#### CHAIN OF CUSTODY LOG

DATE		RELEASED BY		RECEIVED BY	PURPOSE
05/29/2003	Name	Temporary Storage	Sign. Name	MOORE, KIM	Aliquotting
5.29.3	_Sign. Name	Kimberly-Moore	Sign. Mame	STORAGE	STORAGE
	Sign. Name		Sign. Mame		
	Sign. Name		Sign. Name		
.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	Sign. Name		Sign. Name		
	_Sign. Name		Sign. Name		
	_Si.gn. Name		Sign. Name		
	_Sign. Name		Sign. Name		
	_Sign.     Name		Sign. Name		
	Sign. Name		Sign. Name		
MOLKETER C	TXHD4			STORAGE	
the second term of the second builded marked by the second mark the second by the second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second seco	PAR	DIGLEANT COL	or or a contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contract of the contra	BOXZROWZCOL	

PULL LIST FOR WORKLIST(S) TXMP4

PAGE 3

05/29/2003

WORKLIST : TXHP4

ACCESSION PARTICIPANT UNIT CODE

STORAGE BOXZROW/COL

047425H

2552259

39433N

Z000366/A/1/ Split Received

Screening Aliquot Chain of Custody

TOTE: 01850

#### CHAIN OF CUSTODY LOG

PAGE:

23 DATE RELEASED BY RECEIVED BY PURPOSEZAMIT ALIQ **ECOC** MICROLOG Name **STORAGE STORAGE** Sign. Sign. Elizabeth David **ALIQUOT** Mame 5.29.9 STORAGE **STORAGE** Name QUEST DIAGNOSTICS \_Sign. "Sign" Name Name Sign. Sign. Mame Hame Sign. Sign. Name Namo Sign. Sign. Mame Name Sign. Sign. Name Mame Sign. Sign. Mame Mame Sign. Signa Name Mame

. 12	2003	NIDA	CHAIN OF	CUSTODY	PRE-LOG	MANIFEST	PAGE: 1
SEC SUM	CLIENT CLIENT	REQ NUM	BATCH MUM	DATE REC'D	TIME REC'D	REC CODE	
1	51015032	0085189	05290202	05/29/20	003 9:00	MHV. L.VNW	E01 047425H

Screening Test Results

MIDA SYSTEM SOF DAUG SCREEN

WORKLIST: TYMSAPE LOAD: 0529007

BUILT: 05/20/2003 2:00 PM BY: LVNED01 CUPS: 1-46

2:08 PM BY: LVMED01 CUPS: 47-79

TOTE NUMBER: 01851

EHT BY: SEL EY:

INTERPRETED BY: REVIEWED/ RELEASED BY:



Sakri Karim
Mohammad Ghazizadeh

5/29/03 5/29/03

05/29/2010 2:13P PAGE: 1

。(第4)第4)P**01** 

#### ALIQUOT CHAIN OF CUSTORY LOG

	0.10 m (0.00 m) 1 m (1.10 m) 1 m	tur www.	TOUT LOD	
DATE	REVEASED BY	R	ECEIVED BY	FURPOSE
5729703 .	MAME DAVIS, ELIZABETH	_ SIGN MAME	Sakri Karim	Transfer
5/29/03	STON. See Ku'	275 757 274.4 4		
	NAME Sakri Karim	NAME	Olympus _50/	Screen On Olympus erform Additiona
5/29/3	SIGN.	STGM	Selen P	ertorm Additiona
5/29/3	Olympus	. 1 18-12 18	mp sax	alidity Checks
1/2//3	SIGH. Sakri Karim	. SIGN NAME	110011	To Discard Aliquots
	STGH.	STON.		
	NAME			· · · · · · · · · · · · · · · · · · ·
***************************************	SIGH.	SIGN MAME		
	SIGN	SIGN		
	SIGN.			
	NAME	HAME		
	SION. MAME	SIGH		
	SIGN.	SIGN		
	NAME	NOME		ARCONOMICHOROM OLE ARC
	SIGN. MARKE	SIGH		
	SIGN.	SIGN.		
	NAME			
	SION. NAME	HOME		
	SIGN.	GION		
	C OH.	STON.		
	NAME	MOME		

MIDA SYSTEM SAP DRUG SCREEN
WORKLIST: TXNSAP2 LOAD: 0529007
BUILT: 05/29/2003 2:00 PM BY: LVNED01 CUPS: 1-46

NDABWP01 85/29/2003 2:13P PAGE: 5

2:08 PM BY: LVNED01 CUPS: 47-79

TOTE NUMBER: 01851

ENT BY: \_\_\_\_ REL BY: \_\_\_\_

SEQ INSTRID ACN PARTICIPANT UC ORDERED

47 2317 **047425**H 2552259 39434N

CHSTRUMENT: SOT MORKLIST: TXMSAF2 Load:/0529007 01/29/2000 5 59:30 PM All calibrator absorbance values are An Range. Been QC DK Blind GC DK Reviewed and Verified by \_ EUP ACCESSION PART-ID INST-ID COMMENTS 1 XBELOW THRESHOLD AMP = (0.500) DARB ⇒ (0.695) BENZ ≈ (0.718) ; 90 ID = 902L = (0.819) TEO = (0.758) 720 = (2 175) HETD = (0,796) METQ = (0.865) OPI2K = (0.923) PCP = (0.746) PROP = (14.0) = (0 607) CREA CREAR = (14.0) PH = (6,90) PHE = (6.90)RITHRAN = (0)

47 047425H 2552259 2317 HITROL = (MEGATIVE) :

# Laboratory Internal Chain of Custody

Worklist TXHP4

(Steroids)

All and the second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second seco				
Proceedings				
o se de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición de la composición del composición de la composición de la composición del composición de la composición de la composición de la composición de la composición del composición de la composición del composición del composición del composición del composición del composición del composición del composición del composición del composición del composici				
A control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the cont				
***************************************	SIGN. NAME	 SIGM. NAME		ALETS
A CRESISTER OF STREET STATE OF STREET	SIGN. NAME	 SIGN.	VICTOR	2003
1777 Proper of the Halland State	SIGN.	SIGN. NAME	MAY 3	
				BB000784

## NO COLLECTION SITE INFO GIVEN

29 WS Not Defin	947425H	2552259	•		51015032	08)	<b>38</b> 5189
440 1100 2001			IR#1		IR#2		WANT
ANABOL		MASK	***************************************	CLEN	DNR	PRO	DMR
MANIM	DNR	BOLDM	DNR	DIANM	DNR	METENM	DNR
The FLUORM	DNR	MESTM	DNR	METHYM	DNR	TRENM	DNR
^NDATWP06 WORKLIST: TXHP4 5:48P PAGE: 16		29001 PR	OCEDURE	IV — ANABOL	IC AGENTS	SCREEN 05	3/29/2003
SEQ DEPT :	RM DIL ORD	UC			CLIENT #	F:	EQ#
29 WS Not Defi	047425H	TT 12 (III			51015032		085189
	RT	*************	IR#1	# 874 4 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	IR#2		QUANT
/100.110.110.000.0001							
ANABOL		MASK		CLEN	DNR	PRO	DMR
иани'	NMR /	BOLLDM	DHR	DIANM	DINR	METENM	DHR
FLUOXM	DNR /	MESTM	DNR	METHYM	DNR	TRENM	DHR
MIBOLM	DNR	METANM	DMR	DROSM	DNR	BOLLAM	DHR
CLOSTM	DHE	DIMAXO	DNR	HORETM	DNR	OXMITH	DHR
OXYMES	DNR	DHCMTM	DMR	FORM	DNR	FURAZM	DMS
STAIM	DNR \TZ	E RATIO	DMR	DHT	DNR	REM1	DNR
HRAMP4	RAM T	E QUANT	DHR				
CONTINUE	ED	•		T/E QUANT	DNR		
30 WS Not Defi	Ø47434H ned	255164	3		51015032	é	085425
	RT		IR#1 _	1	IR#2	to per upo mino mino to co	QUANT
ANABOL	\$	MASK	All gales per the salesty ray die waters core park	CLEN	DMR	PRO	DMR
NANIT	DHR	BOLDM	DNR	DIANM	DMR	METENM	RMC


BB000785

GC/MS Autotune

Instrument: GCMS # 12
Fri May 30 14:35:42 2003

#### D:\MSDCHEM\1\5973N\ATUNE.U

Mass	69.00	Mass	219.00	Mass	502.00	A-1000		
Ab	494738	Ab	230564		25308	Ion Pol POS	MassGain	490
Pw50	0.61	Pw50	0.62	Pw50	0.62		MassOffs	- 8
	ì		A				AmuGain	2415
	Á		łį		4 1	EleEnergy 69.9		133
	1				li l	Filament 2	Wid219	0.002
			[]			D-m-11 24 01	DC Pol	NEG
ļ	11		11			Repeller 34.81 IonFocus 90.2	uen	ON
	11 .				1	EntLens 14.0	HED	ON 1212
			!!			EntOffs 19.07	EMVOILS	1212
			li l			DIRECTED 13.07		
					11		Samples	8
					1) i	PFTBA OPEN	Averages	3
· '			11				StepSize	0.10
			<i>i</i> ( )		11 1	Zones:		
ļ	[ ]				]		Foreline	74
						MS Quad 150		
	1							
			! ! !					
					in l			
,	/	,	/ h					
	77-7	7				·		
66	71	216	221	500	505			



**Steroid Positive Control** 

Vial: 44

: GCMS # 12

Operator: ds

Multiplr: 1.00

Inst

Data File : D:\MSDCHEM\1\DATA\0530HP4\STERSTD2.D


Acq On : 31 May 2003 12:01 am

Sample : STD 0529001

Misc

MS Integration Params: NA

(RTE Integrator) Quant Method:



STERSTD2.D TXH P4.M Sat May 31 00:09:27 2003

Data File : D:\MSDCHEM\1\DATA\0530HP4\STERSTD2.D

Acq On : 31 May 2003 12:01 am

Sample : STD 0529001


Misc

MS Integration Params: NA

Vial: 44 Operator: ds

Inst : GCMS # 12

Multiplr: 1.00



STERSTD2.D TXH P4.M

Sat May 31 00:09:27 2003

Data File: D:\MSDCHEM\1\DATA\0530HP4\STERSTD2.D

Acq On : 31 May 2003 12:01 am

Sample : STD 0529001

Misc

Operator: ds


Inst : GCMS # 12

Multiplr: 1.00

Vial: 44

MS Integration Params: NA

Quant Method: (RTE Integrator)



STERSTD2.D TXH P4.M

Sat May 31 00:09:28 2003

Data File : D:\MSDCHEM\1\DATA\0530HP4\STERSTD2.D

Acq On : 31 May 2003 12:01 am

Sample : STD 0529001

Misc


MS Integration Params: NA

Quant Method : (RTE Integrator)


Vial: 44 Operator: ds

Inst : GCMS # 12

Multiplr: 1.00



Steroid Negative Control



NEG2.D TXH P4.M

中国大型代表的政

Sat May 31 00:19:33 2003

Page 1

Vial: 45

: GCMS # 12

Operator: ds

Multiplr: 1.00

Inst


Data File: D:\MSDCHEM\1\DATA\0530HP4\NEG2.D

Acq On : 31 May 2003 12:11 am

Sample

Misc

MS Integration Params: NA



NEG2.D TXH P4.M Sat May 31 00:19:34 2003

Data File : D:\MSDCHEM\1\DATA\0530HP4\NEG2.D


Vial: 45 Acq On : 31 May 2003 12:11 am Operator: ds

Sample

Inst : GCMS # 12 Misc Multiplr: 1.00

MS Integration Params: NA

Quant Method: (RTE Integrator)



NEG2.D TXH P4.M Sat May 31 00:19:34 2003

Vial: 45

: GCMS # 12

Operator: ds

Multiplr: 1.00

Inst

Data File : D:\MSDCHEM\1\DATA\0530HP4\NEG2.D

Acq On : 31 May 2003 12:11 am


Sample

Misc

MS Integration Params: NA

Quant Method : (RTE Integrator)

(RIE Integrator)



Steroid Water Control

Data File : D:\MSDCHEM\1\DATA\0530HP4\WATER2.D

Acq On

: 31 May 2003 12:21 am

Vial: 46

Operator: ds


Sample Misc

: GCMS # 12 Inst

Multiplr: 1.00

MS Integration Params: NA

Quant Method: (RTE Integrator)



TXH P4.M WATER2.D

Sat May 31 00:29:41 2003

Data File : D:\MSDCHEM\1\DATA\0530HP4\WATER2.D


Vial: 46 Acq On : 31 May 2003 12:21 am Operator: ds

Sample

Inst : GCMS # 12 Misc Multiplr: 1.00

MS Integration Params: NA

Quant Method: (RTE Integrator)



WATER2.D TXH P4.M

Sat May 31 00:29:41 2003

45:200-2000-6

ASSESSION OF STANSFARTA

allybligid

-34-24-24

Vial: 46

Inst : GCMS # 12

Operator: ds

Multiplr: 1.00

Data File : D:\MSDCHEM\1\DATA\0530HP4\WATER2.D


Acq On : 31 May 2003 12:21 am

Sample

Misc

MS Integration Params: NA

Quant Method : (RTE Integrator)



Specimen Acc. # 047425H

Data File: D:\MSDCHEM\1\DATA\0530HP4\047425H.D

Acq On : 31 May 2003 5:16 am

Sample


Misc

MS Integration Params: NA

Vial: 75 Operator: ds

> Inst : GCMS # 12

Multiplr: 1.00



TXH P4.M 047425H.D

Sat May 31 05:24:54 2003

Data File: D:\MSDCHEM\1\DATA\0530HP4\047425H.D

Acq On : 31 May 2003 5:16 am

Sample Misc


Vial: 75 Operator: ds

Inst : GCMS # 12

Multiplr: 1.00

MS Integration Params: NA

Quant Method: (RTE Integrator)



047425H.D TXH P4.M

Sat May 31 05:24:55 2003

Data File : D:\MSDCHEM\1\DATA\0530HP4\047425H.D

Acq On : 31 May 2003 5:16 am

Sample :

Inst : GCMS # 12


Operator: ds

Vial: 75

Misc : Multiplr: 1.00

MS Integration Params: NA

Quant Method : (RTE Integrator)



047425H.D TXH P4.M

Sat May 31 05:24:55 2003

Vial: 75

Inst : GCMS # 12

Operator: ds

Multiplr: 1.00

Data File : D:\MSDCHEM\1\DATA\0530HP4\047425H.D


Acq On : 31 May 2003 5:16 am

Sample

Misc

MS Integration Params: NA

Quant Method : (RTE Integrator)



Laboratory Report

Acc. # 047425H Spec. I.D. # 0085189 Donor I.D. 2552259

<b>5</b>	ima gali, pica	·	1	1		·	1					-	1									
	CERTIFYING SCI	Masking Agents: Probeneció	Stanozolol Metaboli Androstendiol/DHEA	Retabolite, Midolerone Metabolite Norandrostendione/Norandrostendiol	Mesterolone L/or i	Dihydrofestostero Ethylestrenol/Nori	Bolasierone Melabolile, Bol Closiebpi Metabolile, DMCNT	Anabolic Agents:	Drug Class Tested	NASKING AGENTS	Hasking Agents	ANABOLIC ACENTS	Anabolic Agents	Hd	CREATININE	Integrity Checks	iests Ordered: 394348	FINAL	1 0085189 0% 7425H  Client Site Locatio  REASON FOR TEST; NO  DUMOR ID VERIFIED:	2552259	LONG BEACH, CA 90803	51815032 ARÉA/ROBIE/STOP: XXXXXXX CDT BOS
	CERTIFYING SCIENTIST, MOHAWHAD GHAZIZADEH >> REPORT CONTINUED ON NEXT PAGE ((		70100	Nandro	anon.	Unity of octaon in the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of	ite, DHCNT			Magalive		Regative		5.5	286.3 mg/dL Negative		39434K (BUS PROFILE T WARIT)		85189 047425H 05282003 01:03PK 05292003 01ient Site Location: REASON FOR TEST: NOT SPECIFIED DUNOR ID VERIFIED: EMPLOYER REPRESENTATIVE			STOP: XXXXXXX
100			B5.	tone/ tone/ tone/ tone/ tone/ tone/ tone/ tone/	(Dianabot,	el fachid	e, Clenbulerol,							6.8-5.4	>20 mg/dL	Acceptable Range			PK 05292003 05312003 6;44PK	l		
									1 1 1													5 5 5 5
											4											
	`	7 4 1 4 1																				ļ

Certifying Scientist Resume

#### MOHAMMAD R GHAZIZADEH

225 S Stephanie St Henderson, Nevada 89012 (702) 492-6080 (H)

#### Objective:

A challenging position in an analytical/or research laboratory.

#### SUMMARY:

- Over 15 years Clinical Laboratories / Toxicology experience
- Master degree in Science/ Analytical Chemistry
- · Bachelors degree in Science/ Pharmacy
- · Comprehensive background in all phases of Clinical Laboratories
- Experienced with a variety of Toxicology devices such as GC/MS, TDX, Hitachi, Cobas
- · Able to thoroughly research and review analytical data
- · Bring projects to completion under budget deadlines

#### Employment:

SmithKline Beecham Clinical Laboratories / Quest Diagnostics, Dallas, Texas October 1988-July 2001.

Quest Diagnostics, Las Vegas, Nevada January 2003-Present.

#### GC/MS Analyst/ Lead Technologist:

Forensic Toxicology. Responsible for operation and maintenance of Hewlett-Packard GC/MS system. Duties included data analysis, method development, quality assurance/quality control, standard operating procedures, and training personnel.

#### Lead Certifying Scientist, Forensic Toxicology:

Responsible for Certification of Positive and Negative Forensic drug screens. Duties included review of analytical data, assure compliance with standard operating procedures, answer technical questions for clients and Medical Review Officers, and help in revision of SOP. I serve as an expert witness and technical resource for SBCL/ Quest Diagnostics external customers.

<u>Teaching Assistant, University of Louisiana, Monroe, Louisiana</u>
<u>September 1986-</u>
<u>December 1988</u>

Supervised undergraduate students with AA, HPLC, and Thermospray LC/MS/MS in Chemistry Lab.

#### Education:

Northeast Louisiana University
Master of Science/ Analytical Chemistry, 1990

Thesis Title: Solid - Phase Extraction and Thermospray LC/MS/MS for the detection of Marihuana and its Major Metabolite.

Northeast Louisiana University Bachelors of Science / Pharmacy, 1984

<u>Certified Toxicological Chemist</u> National Registry in Clinical Chemistry, certification No.2289, 1992.

Athletic Scholarship for Soccer, 1980-1984.

Responsible Person Resume

## Victor Uralets, Ph.D.

Dr. Uralets received a Doctorate Degree in Organic Chemistry from The Institute of Organoelement Compounds of the Academy of Sciences of the USSR in 1972. He completed a Post Doctoral Fellowship in Analytical Instrumental Analysis at the Eindhoven Technical University in the Netherlands in 1978.

Following graduation from the Moscow University Victor Uralets was engaged in a project on "synthetic food" as a research scientist in the Institute of Organoelement compounds and was particularly focused on detection and identification of volatile food flavor components.

Since 1980 Dr. Uralets has held positions as a Senior Analyst and Scientific Director in the Olympic laboratory Moscow (Anti-Doping Center), which provided full range of athletic drug testing mandated by the International Olympic Committee.

Since 1992 Dr. Uralets is a Director of Sports Testing in San Diego, CA, laboratory for Nichols Institute and its successor companies: Corning Clinical Laboratories and Quest Diagnostics Incorporated.

Dr. Uralets is currently (since February 2003) a Technical Director in the Las Vegas Quest Diagnostics CHW laboratory and is responsible for Sports and HPP drug testing.

41125218 AREA/ROUTE/STOP: XXXXXXX

BALCO LABORATORY
ATTN: VICTOR CONTE
1520 GILBRETH RD
BURLINGAME, CA 94010



PART	TICIP	ANT NAME		PARTICIPANT ID		ROOM NO.	AGE	SEX	PHYS	ICIAN	
1	005	72									
PAGE	REGI	DISITION NO	ACCESSION NO.	LAB REF. #	COLLECTION DA	TE & TIME	LOG	-IN-DI	ATE	REPORT DATE	& TIME
_ 1	9	009147	048757H		05302003	}	06	022	2003	06062003	3:15PM

REMARKS Client Site Location: REASON FOR TEST: NOT GIVEN

DONOR ID VERIFIED:

REPORT STATUS		TEST	RES	SULT	UNITS	REFERENCE	SITE	
REPORT STATUS	FINAL	1521	IN RANGE	OUT OF RANGE	UNITS	RANGE	CODE	
REPORT FO	np •	BALCO	LABORATO	Y - 41125	218			
indicate in	J. ( )		VICTOR (					
			GILBRETH					
			NGAME, CA	* T 100 0 0 0 0 0 0 1	,			
		201121						
Tests Orde	ered: 3828	9N (STEROI	1 W/NIT					
		•						
Integrity	Checks				Acceptable :	Range		
-								
CREATINI	NE		223.7 mg/	<b>1</b>	>20 m	g/dL		
NITRITES		1	Megative :					
pH ·			6.7		4.5	-8.9		
Anabolic A	Agents				一十三			
					フて			
ANABOLIC	AGENTS		regative :					
					<b>'</b>			
Masking A	gents							
			<b>J</b> edžišálš					
MASKING A	AGENTS	,	Negative					
D 01								
Drug Class	s Tested							
Anah	olic Agents	<b>:</b> •						
Allab	orre ngener	••						
Bo	lasterone N	Metabolite.	Boldenon	Metaboli	te, Clenbutero	1,		
C10	ostebol Met	tabolite. D	anazol &/	r Metabol	ite, DHCMT			
		comethyltes						
					etabolite,			
Etl	hylestrenol	1/Norethand	olone Me	abolite,	Fluoxymesteron	e		
Me	tabolite, E	ormebolone	Metaboli	e, Furaza	bol Metabolite	,		
Me	sterolone 8	/or Metabo	lite, Met	andienone	(Dianabol,			
Me	thandroster	nolone) Met	abolite,	ethandric	1 &/or			
Me	tabolite, N	Methenolone	&/or Met	abolite, N	ethyltestoster	one		
Me	tabolite, N	Mibolerone	Metabolit	, Nandrol	one/			
					ite, Oxandrolo	ne		
& / c	or Metabol:	ite, Oxymes	terone, O	kymetholor	e Metabolite,			
Sta		etabolite,			tendione/			
	>> REPORT	CONTINUED	ON NEXT P	AGE <				

41125218 AREA/ROUTE/STOP: XXXXXXX

BALCO LABORATORY
ATTN: VICTOR CONTE
1520 GILBRETH RD
BURLINGAME, CA 94010



PARTICIPANT NAME PARTICIPANT ID ROOM NO. AGE SEX PHYSICIAN	
100572	
PAGE REQUISITION NO ACCESSION NO. LAB REF. N COLLECTION DATE & TIME LOG-IN-DATE REP	ORT DATE & TIME
2 9009147 048757H 05302003 06022003 06	3:15PM

REMARKS Client Site Location: REASON FOR TEST: NOT GIVEN DONOR ID VERIFIED:

REPORT STATUS		TEST	RE	SULT	UNITS	REFERENCE	SITE
REPORT STATUS	FINAL	TEST	IN RANGE	OUT OF RANGE	UNITS	RANGE	SITE CODE
REPORT F	OR:			Y - 411252	18		
			VICTOR				
			<b>GILBRETH</b>				
		BURLI	NGAME, CA	94010			
Drug Clas	s Tested						
An	drostendio	1/DHEA (T/E	Ratio >	(). Trembolo	one Metaboli	te	
		.,					
Mack	ing Agents						
		Epitestoste	rone (> 2	OO no/mL)			
22	obelicata,	LPI CCD COD CO					
	CEDETEVIN	G SCIENTIST	CAPOLA	DERSON			
	CERTIFIIN	G SCIENTISI	CAROL				
	DECETION A	VID DOOGEGGE	n rat mire	TAR TIECTO	UUG CROTTRIRI	D LABORATORY.	
SPECIMEN	RECEIVED A	ND PROCESSE	u in ine	LAS VEGAS DI	nns Ceriffie	D LABORATORI.	
LAB:		gnostics In	d-Las veg	a <b>s</b>			
		h Burnham					
	Las Vegas	NV 89119					
			>> END OF	REPORT <			
	•						

. .

02/2003 13:40 +		Date, Grando Hind, Juliania, Film	PAGE 83
cartify that I have Thressed the ab	Sheffield, Gary	The following inclividuals have consented to the notor hereby advocwinedge that they have been a and Treatment Program, and that if they fail with	Dete: Wayno
seed the above algratures:	2560895	of the second	GR D
		t for collection of a unine apecimen on the clud of the requirement that they be tested for oid cause to give a specimen, they will be to	MAJOR LEAGUE BASEBALL'S DRUG PREVENTION AND TREATMENT PT
i have so	7.5		ECTION LOG BASEBALL'S TREATMENT PROGRAM Attenta Braves
ATLANE OF COLLECTION		day of 24.14. 2003, and by their signature prohibited substances pursuent to the MLB Joint Drug Preventioned as it their specimen had tested positive.	OG
OPQ.	200	Joint Drug Prever	Page 1 of



# UCLA Olympic Analytical Laboratory UCLA School of Medicine 2122 Granville Ave Los Angeles CA 90025 Phone (310) 825-2635 FAX (310) 206-9077



## CONFIDENTIAL DRUG TESTING REPORT ZZ2315 (7H406)

May 11, 2006

IRS-CI

Attn: Special Agent Jeff Novitzky 55 South Market Street, Suite 815 San Jose, CA 95113

UCLA CODE: ZZ2315 7H406 Specimen Number: 052517

The laboratory analyzed the urine specimen listed above for anabolic androgenic steroids, masking agents, and anti-estrogenic compounds.

**ANALYTICAL FINDINGS:** The urine sample identified above contains clomiphene and tetrahydrogestrinone (THG). The screen TE ratio of the urine sample is approximately 2.7. The IRMS measurements of  $5\beta$ -androstanediol,  $5\alpha$ -androstanediol, and  $5\beta$ -pregnanediol are -26.4, -26.8, and -21.2% (per mil) respectively; these IRMS data are outside of our normal ranges.

Please let us know if we may be of further service to you on this matter or any related issue.

Don H. Catlin, M.D

Director

This report shall not be reproduced except in full, without the written approval of the laboratory.

# ORENSIC DRUG TESTING CUST OY AND CONTROL FORM



The second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the second state of the se

51015032 0085157 SPECIMEN ID NO.

STEP 1: COMPLETED BY COLLECTOR OR EMPLOYER REPRESENT	ATIVE LAB ACCESSION NO.
A. Employer Name, Address, I.D. No.	B. MRO Name, Address, Phone and Fax No. 1187 17 46 (3446)
957 670	No. 2
	Paraka encomme to
F. 198 341	8 % (\$9) 3 % ·
4194 \$24 a. tr \$953 C	A MANAGER DO HOUSE
16 金髓2 (5 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	An Estimated state of the
C. Donor SSN or Employee I.D. No.	
D. Donor Name: Last: 1 1 59 # 7 # 1 150 15 15 15 15 15 15 15 15 15 15 15 15 15	ELDI First F. F. F. B. T. S. T. B. S. J. B.
E. Donar ID Verified: Photo ID AEmp. Rep.	
F. Reason for Test: Pre-employment (1) Random (3) Re Return to Duty (6) Follow-up (23)	asonable Suspicion/Cause (5) Post-Accident (2) Promotion (22)
G. Drug Tests to be Performed:	
1 . 5940 A. ALL F. 51318 & 57921	•
H. Collection Site Name: ACTUSE 7446 Col	lection Site Code:
Address:	Collector Phone No.: 10 6 5 8469
City, State and Zip: Alv RHIVE Self CA.	Collector Fax No.: 51/ 1 7 ////
STEP 2: COMPLETED BY COLLECTOR	
Read specimen temperature within 4 minutes. Is temperature Specimen	
	Single None Provided (Enter Remark) 🗵 Observed (Enter Remark)
REMARKS	
STEP 3: Collector affixes bottle seal(s) to bottle(s). Collector dates seal(s).	
STEP 4: CHAIN OF CUSTODY - INITIATED BY COLLECTOR AND CO	
V MONTON ON DIVE AM	SPECIMEN BOTTLE(S) RELEASED TO:
Signature of Collection	Quest Diagnostics Courier FedEx
LIACE RENDERVY 11 9100	Airborne Other
(Print) Collector's Name (First, MI, Last) Date (Mo./Day/Yr.)	Name of Delivery Service Transferring Specimen to Lab
RECEIVED	Primary Specimen   SPECIMEN BOTTLE(S) RELEASED TO:
Signature of Accessioner	Bottle Seal Intact
(Print) Accessioner's Name (First, MI, Last) Date (Mo./Day/Yr.)	No, Enter Remark Below
STEP 5: COMPLETED BY MEDICAL REVIEW OFFICER (IF REQUIRED  I have reviewed the laboratory results for the specimen identified by this form in accordance with applicable.)	·
□ Negative □ Positive □ Test Not Performed □ Test Cancelled REMARKS □	re requirements. way determination/verification is:
(PRINT) Medical Review Officer's Name (First, MI, Last)	Signature of Medical Review Officer Date (Mo. / Day / Yr.)
STEP 6: COMPLETED BY DONOR	ch specimen buttle used was sealed with a temper-evident seal in my presence; and that the information and
numbers provided on this formand on the label affixed to each specimen bottle is correct.	Source Source and a temper-evident seal in my presence, and met me information and
X Cam. DA	ery fonds 6/4/03
Signature of Donor	(FRINT) Donor's Name (First, MI, Last)  Date (Mo.:Day/Yr,
I Marriage Share No. 1	Description U //CY /04

For record, the samples from UCLA folder number ZZ 2040 lab code 2FT were hand delivered to UCLA Olympic Laboratory on 5/5/04 and were received by Brian Bishop. The samples were received at room temperature.

Brian Bishop

## RECEIVING CHECKLIST

The sam	ples are fr	om (circle):	DOD*	NCDFS	NFL	UCLA	UNIV
			USA		HER IN	TERNAL	SPEC*
UCLA Cod	ie: <u>2</u> FT		Clie	nt Folder	#: 22 20	540	
			Spor	=: Subjec			
Check AI	LIQUOT.SOP	appendix A for	MENU:	(circle)			
I	EMIT II	CF SMART	DIU		C THC	THC ONTRAK	OPI ONTRAK
AMPH	B-BLOCKE	RS BBII B2	AG HCC	HRMS	THG :	EPO	
SP: (TRIAGE,	BLOOD, PILL,	etc.)		•			
See ALIQ Total nu	UOT.SOP for mber of san	a descriptionples:	circle to NCDF versa with red_t	pe of kits u (1999 ty kit) DO a white ape over	quot base sed Berl: pe); USAI D type(pl screw cap the cap) ULOF typ	inger Ve DA (1999 Lastic bo p and an	ersapak type, ottle
Total nur	mber of QC'	s:	_ (if ne	eded, <b>ad</b>	d 1 for B	IQC)	
Total nur	mber of Cal	's:	_ (if FUI	L IOC mer	u, USADA	(OOC & IC	2) .
If batche Email all	ed, Group C l parties c	ode: oncerned.	Clien	t, Folde:	r #:		
Initial t	he items b	elow as they	are comp	leted.			,
	Pos HCG Q	C added. Chec	k HCG	QC log.			•
	HQC added	and e-mailed	all par	cies cond	erned.		
	Manifest, code #'s	if there is o	one, foldossed out	der # in	upper ri	ght corn	er, lab
<u> </u>	Folder proform, Reconstruction Integrity paperwork	eparation (shi elving Checkli form, (ASF's, included).	ipping a ist, Sam Officia	ir bill, ple Custo Record'	Batch Ch ody-Docum s) QC fo	ain of Coentation	ustody of Seal d other
	DDIMS STER aliquottee FORM is do	? 7 corrected. d are entered ouble checked	Menu do as "X" i against	ouble che n all as DDIMS ST	cked. Sa says. SP EP 7 ent	mples not ECIAL AL: ries.	LQUOT
	Receiving	group folder	data-ent	ry compl	eted.		
	"A" and "I	3" samples sto	red. Des	cribe (c FRIDGE #	ircle): ( 16,#17,#	COLDROOM 18,#19,29	∍.
form appr	oved Au 3	3/31/04				PAGE 1	1 OF 2

#### UCLA OLYMPIC ANALYTICAL LABORATORY

# SAMPLE CUSTODY - DOCUMENTATION OF SEAL INTEGRITY (IRS-CID BAG)

FOLDER ZZ2040

UCLA	BOTTLE			
CODE	NUMBER	A *	В *	If not intact, describe below
2FT01	0	0	o	
2FT02	0	0	0	
2FT03	0085174	x	x	
2FT04	0085159	х	x	
2FT05	0113293	х	х	
2FT06	0085157	х	x	
2FT07	0085418	х	х	
2FT08	O	О	o	

<sup>\*</sup> Instructions: Verify by "X" that the custody of each specimen is intact. If not intact, record "NO" and describe in the space provided.

Note: Entries for internal QC are listed as "O".

The above samples were received in the condition stated above.

Signature	B Sily	Date 5/7/04
Print	Brian Bishop	Time 5://pm
Verified	by (initials and date	ASJ 5/7/04

## Sample Identification and Chain of Custody

Bottle Number	Original Code
52511	QCN237
52512	2FT03
52513	QCN224
52517	2FT06
52524	2FT04
52525	2FT05
52526	QCN235
52527	2FT07

Each 2FT sample consisted of an A and B container, the contents of which were transferred to an A and B bottle, respectively. Each QCN was poured into an A and B bottle.

Yvonne Chambers transferred the samples and verified each Bottle Number and corresponding Original Code and then passed custody to Paul Scott.

Paul Scott witnessed the transfer and independently verified each Bottle Number and corresponding Original Code and then took custody of the bottles.

Yyonne Chambers March 1, 2006

V A L

Pavil Scott

March 1, 2006

•

41125218 AREA/ROUTE/STOP: XXXXXXXX

EALCO LABORATORY
ATTN: VICTOR CONTE
1520 GILBRETH RD
BURLINGAME, CA 94010






PAR	TICIPANT NAME	PARTICIPANT IO	FOOM NO	AGE SEX PHYS	ICIAN	
1	00573					
PAGE	PEQUISITION NO ACCESSION NO	LAB REF #	COLLECTION DATE & TIME	LOG-IN-DATE	REPORT DATE	i & TIME
1	9008589 050715H		06052003	06062003	06102003	2:47PM
<u></u>	3000503	1000		100002000	100202003	1 2 : 4 / 3/81

REMARKS Client Site Location:
REASON FOR TEST: UNKNOWN
DONOR ID VERIFIED: UNKNOWN

REPORT STATUS	FINAL	TEST		OUT OF RANGE	UNITS	REFERÊNCE RANGE	SITE CODE
REPORT FO	DR:	ATTN: 1520 (	LABORATOR VICTOR O ILBRETH R GAME, CA	D : .	219		
Tests Orde	ered: 3828	en (stercii	1 W/NIT)				
Integrity	Checks				Acceptable I	Range	
CREATININ	IE		25.7 mg/c	E :	>20 mg	g/dL	
NITRITES pf		r	egative 5.3		4.5-	-8.9	
Anabolic A	gents			. :			
ANABOLIC	AGENTS	1	Jegative				
Masking Ag	;ents						
MASKING A	GENTS:	7	legative				
Drug Class	Tested		,				
odsnA	olic Agents	i :					
Clo (De Din Eth Met Met Met Met No:	stebol Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication Metabolication	abolite, Da comethyltest terone, Dro Norethandro (normebolone) / Or Metabol (normebolone) Metabolethenolone (norme/Norano (norano (nor	nazol %/o osterone) mostanolo olone Met Metabolit ite, Meta bolite, N %/or Meta (etabolite rostendo erone, Ox	metabolime &/or Mabolite, abolite, e, Furaza andienone lethandric bolite, Mandroll Metabolime/Andros	etabolite, Fluoxymesterone bol Metabolite, (Dianabol, 1 &/or (ethyltestostero one/ ite, Oxandrolor e Metabolite,	e P	

41125218 AREA/ROUTE/STOP: XXXXXXX

BALCO LABORATORY
ATTN: VICTOR CONTE
1520 GILBRETH RD
EURLINGAME, CA 94010



PARTICIPANT NAME

100573

PAGE REQUISITION NO ACCESSION NO. LAB REF N: COLLECTION DATE & TIME LOG-IN-DATE REPORT DATE & TIME 2 9008599 050715H 06052003 06102003 2:47PM

REMARKS Client Site Location:

REASON FOR TEST: UNKNOWN DONOR ID VERIFIED: UNKNOWN

REPORT STATUS		TCCT	RE	SULT	LINUTS	REFERÊNCE	SITE
REPORT STATUS	FINAL	TEST	IN RANGE	OUT OF RANGE	UNITS	RANGE	SITE CODS
	_			]	2.0		
REPORT FO	DR:		1	Y - 41125	218		
			VICTOR (	.)			
			ILBRETH I				
		EURLI.	IGAME, CA	34010			
			1				
Drug Class	: Tested						
bing cias	, 10000						
Ano	irostendio	L/DHEA (T/E	Ratio >	), Trenbo	lone Metaboli:	te	
Maski	ing Agents	:					
Pro	benecid, E	Epitestoste.	one (> 20	0 ng/mL)			
	CERTIFYING	S SCIENTIST	CAROL A	DERSON			
		•					
SPECIMEN F	ECEIVED A	ND PROCESSE:	O IN THE I	AS VEGAS	DHHS CERTIFIED	LABORATORY.	
		<del></del>					
	4230 South	gnostics Ind	T-rs ved:				
	Las Vegas						
	Las vegas	110 09119	1				
		,	> END OF	REPORT <			
				·			
				]			
				.			
				ļ			
				1			
				i			
			·.				
			-				

	C	J	
			•



# St. Joseph's Hospital and Medical Center **CHW**

350 WEST THOMAS ROAD Phoenix, AZ 85013 Phone: (602)406-3410

DATE: 08/31/03

MR : (0000)0104-82-47

LABORATORY DISCHARGE REPORT

ACCT: 77572238 NAME: BONDS, BARRY

AGE: 39 YRS SEX : M LOC ROOM:

(Discard daily and weekly reports)

PHYSICIAN: FITZGERALD, JOHN W

09/23/03 0022 ADMIT: 08/31/03

DISCHARGED: 09/01/2003

经收益的基本 医自然性 化二二二甲基甲基二甲基甲甲基甲基

# HEMATOLOGY

TIME: 1830	
TIME: 1830	REFERENCE UNIT
PLATELET 308	150-450 TH/UL
WBC 12.3H	3.6-11.1 TH/UL
WBC 12.3H RBC 12.35.236 - 12.56.25 12.66 12.66 12.66 12.66	4.27-5.73 MIL/UL
RBC (06/04/03 Current)	

RBC (06/04/03	্ট িন্ট ক্রিক্টি <b>23</b> ল কর্মিক্টা, সংগ্রিক্টির বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বিশ্ব বি	4.27-5.73	MIL/UL
100/04/05			
HEMOGLOBIN	14.0	12.9-16.1	GM/DL
HEMATOCRIT	14.0	37.7-51.3	
MCV	13	79-95	
MCH	TO THE RESERVE OF THE PARTY OF A 1 A 1 A 1 A 1 A 1 A 1 A 1 A 1 A 1 A	28.0-32.0	
MCHC	33 8	32.0-36.0	
RDW	15.6H (15.6H)	11.5-14.5	
POLYS % (AUTO)	54.2	46 D-65 O	9
LYMPHS & (AUTO)	) (	25.0-35.0	9
MONO % (AUTO)	5.4	1.0-10.0	
EOS % (AUTO)		0.0-5.0	
BASOS % (AUTO)	0.4	0 0-1 0	9
POLYS ABS		02.0-08.0	TH/III.
LYMPHS ABS	A_RH	1 5 4 0	TH/UL
MONOS ABS		0.1-2.0	TH/UL
EOS ABS	0.1	0.0-0.7	TH/UL
BASOS ABS		0.0-0.2	TH/UL
SLIDE REVIEWED	SCANDONE		,

### CHEMISTRY

DATE: 08/31/03 TIME:

DATE:	
TIME: 1830	
그는 사람들은 문학 기계 학교로 되는 것이 하고 있습니다. 그리고 있는 사람들이 되었다. 그는 사람들이 다른 하는 사람들이 다른 하는 사람들이 다른 하는 사람들이 되었다. 그는 사람들이 다른 하는 사람들이 되었다.	FERENCE UNIT
CHEMISTRY PANELS	9,12,
SODIUM - 139 - 139	134-144 MEO/L
POTASSIUM 3.8	3.6-5.1 MEQ/L
CHLORIDE 112H	101-111 MEO/L
CO2 23f	22-32 MEQ/L
BUN 22	8-24 MG/DL
BUN (03/18/03 Current)	-
PLEASE NOTE NORMAL RANGE CHANGED FOR AGES > 5 YEARS OLD ON 03-18-200	03.
CREATININE 1.6H	0.7-1.2 MG/DL
ニューニュニュニー アン・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・	

GLUCOSE 74-118 ANION GAP 7-15

L = Low, H = High, f = Footnote

CO2........... 08/31/03 1830 CORRECTED FROM 28 ON 08/31/03 AT 2000 BY CGUNNING ANION GAP.... 08/31/03 1830 CORRECTED FROM -1 ON 08/31/03 AT 2000 BY CGUNNING MR-48C (10/98) CONTINUED PAGE

ROY IAN DAVIS, M.D.-MEDICAL DIRECTOR CHAIRMAN OF DEPARTMENT OF PATHOLOGY

E. SMITH COLLUM, M.D. - DIREC CLINICAL LABORATORY SERVI



# St. Joseph's Hospital and Medical Center **CHW**

350 WEST THOMAS ROAD Phoenix, AZ 85013 Phone: (602)406-3410

09/23/03 0022 ADMIT: 08/31/03 LABORATORY DISCHARGE REPORT

(Discard daily and weekly reports)

MR : (0000)0104-82-47

ACCT: 77572238 NAME: BONDS, BARRY

AGE : 39 YRS

SEX LOC : ROOM : 2T22

PHYSICIAN: FITZGERALD, JOHN W

DISCHARGED: 09/01/2003

### CHEMISTRY

TIME	. 1930				<u> </u>	
itue	1630	i wasan ng min <del>a</del> ji da d	J	REFERE	NCE	UNIT
CHEMISTRY PANELS						
CALCIUM	8.OL		화원에 끊힌 생활이다.	8.	9-10 3 -	MG/DL
TOTAL PROTEIN	5.6L			6.3	1 <b>-</b> 7. <b>9</b>	G/DL
ALBUMIN	2.9L		45 Part a 1544 1 112 11 11 11 11	3.	5-4.8	G/DL
ALK PHOS	44 0.7		The state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the s	3	8-126	U/L
BILIRUBIN TOTAL	0.7	toka i se filofici 😹 s		0.	4~2.0	MG/DL
SGOT	33			1:	5-41	U/L
SGPT	38			. 1	7-63 🐪 🖖	U/L
CPK	963H				9-397	U/L
GENERAL CHEMISTRY		general and the the			· 1	
THYROXINE, FREE	.70L			.7	1-1.85	NG/DL
TSH	2.647			.49	0-4:700	UIU/ML
CPK TOTAL	963H			4	9-397	U/L
CPK-MB	2.8	. ಜಾಕ ಜ್ಯಾಸ್ ಮತ್ತಿ ಭಿ}		< -	5.0	NG/ML
CPK-MB INDEX	NA .			<	4.0	
TROPONIN I	<0.3			<	0.4	NG/ML
TROPONIN I (03/17)	/01 Current)					. ,
< 0.5	NG/ML	NEGATIVE	2 HA 1 A		1.19	1
0.5 -2.0		INDETERMINATE				
. 2 4	TATO ARE CITOOT	CONTRACTOR OF MOLOCARDS	AT TATTITIES			4 4, .

> 2.0 NG/ML SUGGESTIVE OF MYOCARDIAL INJURY


L = Low, H = HighMR-48C (10/98)

ROY IAN DAVIS, M.D.-MEDICAL DIRECTOR CHAIRMAN OF DEPARTMENT OF PATHOLOGY

END OF REPORT

PAGE

E. SMITH COLLUM, M.D. - DIREC CLINICAL LABORATORY SERVIC



.

07/24/2006 15:46

3368827

514-630-6399

SMITH

LABO DOPAGE

PAGE 05

PAGE 12/13

Laboratoire de contrôle du dopage INRS - Institut Armand-Frappier 1NKB \* Institut / Striberum / 245 boul Hymus
Polme-Claire (Quitine) HPR (G6
Yéléphone: 514 630-8806
Yéléopteun 314 630-8899
Courriel: christiane.syoneghle/.inrs.ca

Certificate of analysis

Confidential

Testing Authority Dr. Jean Joseph Chief Operating Officer 4510 E. Pacific Coast Highway Suite 320 Long Beach, CA 90804

Collection date:		Reception date	Reporting date			
7 July 2006		11 July 2006	24 July 2006			
Event	٦		Sport			
N/A			N/A			
Collection site			Reference number			
N/A			10001			
Doping control officer		Delivery	Tracking number			
N/A		Fedax	8546 6487 4128			
Number of samples	Sample type	Analysis performed				
10	Urine	Anabolic steroids, masking agents and stimulants				

Sample Code	Results
113781	D-amphetamine; estimated at 278 ng/mL.

Boudreau 18 Danielle Goudreault, M. Sc. Senlor Analysi

Certificate number 06-1653AA

Page 3 of 4

naug - mentar Armana - Lishbier - gante 245, boulevard Hymus Pointé - Claire CA - Québec H9R1G6 Canada

CCOUNT NO.

10001

Signature of Donor

+

SPECIMEN ID NO.

COMPLETED BY COLLECTOR (Green Sections 1, 2, 3, 4 and 6) **ACCOUNT NAME** CDT, Inc. P.O. Box 3247 Long Beach, CA 90803 Ph: 562-986-4200 Fax: 562-986-1207 HPAC 1. TEST TYPE: 2. SITE OF COLLECTION: 3. REMARKS 4. VALIDITY TESTS Final Readings for pH and Specific Gravity determined by the WADA Accredited Laboratory Specific Gravity 6. CHAIN OF CUSTODY - INITIATED BY COLLECTOR AND COMPLETED BY LABORATORY I personally observed the donor identified in the certification section on Copy 2 of this form produce a urine specimen. I initialed and dated the security seals in the donor's presence and provided the donor with the opportunity to observe while affixed the security seals to the specimen bottles. 710 SPECIMEN BOTTLE(S) RELEASED TO: ŹM. ⊠ FedEx ☐ DHL / Airborne Signature of Collector Time of Collection 7/7 106 Janu A. シロ Other. Name of Delivery Service Transferring Specimen to Lab (Print) Collector's Name (First, MI, Last) Date (Mo./Day/Yr.) Specimen Bottle SPECIMEN BOTTLE(S) RELEASED TO: RECEIVED Seals Intect AT LAB: Signature of Accessioner Yes No, Enter Remark Below Date (Mo./Day/Yr.) (Print) Accessioner's Name (First, MI, Last) 5. DONOR CERTIFICATION (Pink section 5 to be completed by Donor) Lertify that Laroduced the ettached urine specimen under observation; that it consists entirely of my own urine; that my specimen bottles were capped and sealed in my presence; that the Specimen Identification Number appearing on this form and that I observed the collector placing his initials on the seal.

CODV 2

PRINT) Donor's Name (First, MI, Last)

Date (Mo./Day/Yr.

336882





July 27, 2006

## Report of Positive Test Result

Barry Bonds has been brought to my attention as having tested positive for a prohibited substance under Major League Baseball's Joint Drug Prevention and Treatment Program. This document constitutes formal notification to the Health Policy Advisory Committee of the above named positive test result. The prohibited substance is D-amphetamine. The collection date was July 7, 2006. The certificate of analysis was sent to HPAC on July 26, 2006.

Bryan W. Smith, M.D., Ph.D.

Independent Program Administrator

Major League Baseball Joint Drug Prevention and Treatment Program

113781 Barry Bonds



CONFIDENTIAL

August 1, 2006

By Fax (Original by Overnight Mail)

Barry Bonds c/o Major League Baseball Players Association 12 East 49th Street New York, NY 10017

Re: Notice of Positive Test

Dear Barry:


This letter is to inform you that on July 7, 2006, you tested positive for a Stimulant. As a result, and pursuant to Articles 4 and 5 of Major League Baseball's Joint Drug Prevention and Treatment Program (the "Program"), you have been placed on the Administrative Track and you will be subject to six unannounced tests over a twelvemonth period expiring on July 6, 2007. These six tests will be in addition to the regular testing prescribed under Section 3.A of the Program. In the event you test positive for a Stimulant in a future test, you will next be subject to a 25-game suspension.

Sincerely,


Commissioner Allan H. Selig

cc:


Eugene Orza Michael Weiner Bryan Smith




30 31 086		1 CCT Zooms Clear	23 24 25	1 c t 20mg	の事と	16 17 18		.25 G Clear	9 10 11	.25 6	166 T 200 mg	2 .3 4			SUN MON TUE	December 2001
•	-25 G			, 25 C.		19	256		12	.75 G		5			WED	
		clear	27		Closer	20		S. S. S. S. S. S. S. S. S. S. S. S. S. S	13			5			UHT	
	. 25 C		28	. 25 G		21	. 25 G		14	. 25 6		7			FRI	es es
			29			22			15			<b>∞</b>		н	SAT	
									<b>Ġ</b>				S A N D P			




	•	
	·	
•		





.



31		24 25 26	17 18 19	10 11 12	3 4 5 START		March 2002
		27	20	13	თ		WED
·	TEST	28 ×	21	14	7		UHT
		29	22	15	8	1 of f	FRI
		30	23	16	9	2 1 Class	SAT
				1.2-251		Sand?	

(	C	<b>J</b>	
	·		

	GS OSF-A MELTH	30 B. 8 28 B. 8 30	V D	1500-A) 1500-22 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-23 1500-2	TA-IN. O NYW-H . MYW-A	9	Daylight Senting Title Beglins G.S. PIAZ-H	SD-197 OFF-888 LA-199	OFF BB	THE DHI. A 1 LA-1A2	Sunday Monday Tuesday	8 M T W 1 F 8 8 4 5 6 7 8 9 10 11 12 13 H 16 16 17 16 19 20 21 22 23 24 25 26 27 28 29 30
		April And of	G.S G.S	CHC-AZ (	NYM-H OR.A	SD-417 GRA18	G.S 6.5	0	DAM-A PAR- V	LAAS LAAA	Wednesday Thursday	11 2002
· 7		ST PATE	G.S G.S	22 *** 324 SA	Hevolutionary War Bernn, 1775 First Counter	BON DINGS	Chairman Thomas Jefferson 1743	23	CS.S G.S	SO	Friday Saturday	6 H T W T F 6 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

2 3 9 8 0

Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday  Sunday
24:55:50 6 5 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7
Thesday A. A. A. A. A. S.
Wednesday Thursday PHI-A-A Coyally bay Wednesday PHI-A-A Coyally b
COLY SBR STL-H COLY SBR STL-H COLY SBR STL-H COLY SBR STL-H COLY SBR STL-H COLY SBR STL-H COLY SBR STL-H COLY SBR STL-H COLY SBR STL-H COLY SBR STL-H COLY SBR STL-H COLY SBR STL-H COLY SBR SBR STL-H COLY SBR STL-H COLY SBR STL-H COLY SBR STL-H COLY SBR SBR STL-H COLY SBR SBR STL-H COLY SBR SBR STL-H COLY SBR SBR STL-H COLY SBR SBR SBR SBR SBR SBR SBR SBR SBR SBR
825 00 00 00 00 00 00 00 00 00 00 00 00 00

	J	

	(Sos: 13)	DAX AIG	- NAWAS	CIN-CS	C. C. 19.0		Sunday	S H T W T F S 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31
<b>y</b>	S\$-424	\$0 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT - 12 PT	130-140 0-140+	NYM - X  (as), Outling	50-A3		Monday	7 6
	SD-425	TB-1818	1000 A	C.S. 4	50-A4		Tuesday	<u></u>
	32,45	7874 19	Tong T	8.8 8.4 8.4	00-A5		Wednesday	C SCIENTING ANTICOLOGIES
A STATE OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PARTY OF THE PAR	22 - HZ7	Z	\$5 B	0 Day (Namanga) 1944			Thursday	02
J	024-428	Can Day	BBS A	る。三年	Nym.	- 100		5· M 1 7 8 14 15 21 22 28 29)
	0 AK - AZ 9	88 821482	36 AK 17239	F X 2	N. W. S.	CB CB C	Saturday	7 × 1 F 6 6 7 19 19 20 24 25 26 27

# June 200

	•	
	r	
,		

The state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the s			All the second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second s
Lasi Quarte:	30.6 22	Way War II Began, 190	
30-G 30	30-G 16 1 CC-1 Yom Kippur Yom Kippur Autumnal Equinox	Labor Day V-J Day, 1945	21 TO S S S S S S S S S S S S S S S S S S
	Chizenship Day 30-G 24	lucsday	Autumn Ste
	25	Wednesday	Autumn Stories  Autumn Stories
	19	mursday	
	First Owarter 20	C)	
	Written, 1914  121  121  121  121  121  121  121	Rosh Hash New Moon  Star-Spandia Banner	October  5 m 1 m 1 F 5  6 7 8 9 10 11 12 13 14 15 16 17 19 19 20 21 22 23 24 25 26 27 28 29 30 31

						-61						r
			24		17	10		ယ		Sun	NOV	
		·25·G	251 ccT	75.G	1016T	111027	. 25- Gylight	4100 T		Mon	November	
			26	17	5	12		21		Tue		
		.25.6	27	754	-25-G	13	. 25. G Hight	6		Wed		MSTELL
			28		<b>)</b>	14		7		Тъи		7
N	<b>3</b>	.25.6	29	28-6	.25.6		. 25.6 Mat	∞		Fri		
NOON			30	63	3	16		9	2	Sat		

The Wed Thu Thu Thu Thu Thu Thu Thu Thu Thu Thu

•

						5
	29	22	15	<b>∞</b>		Sun
	30		16 ICC T	9 166 T 25 & MIGHT	2 1cc T	ecember
	31	24	17	10	ယ	Tue
	. H2717 S C3 .	25	18	11 11	- 25 G MIGHT	Wed
		26	19	12	<b>5</b>	Thu
	1 3 6 Hab		20	13	149EN 5 52.	Fri
2002	-	28	21	14	7	Sat
		**	12-254			

			12-21			-
	29	22	15	<b>∞</b>	1	Sun
						ece
	30 1ccT	231000	16 hat	9	2	ecember
	31	24	17	10	3	Tue
		25 .75-G	18	11	4	Wed
		26	19	12	5	Thu
		27	20 . 25-G	13	6	Fri
2002		28	21	14	7	, 'at

	J	
	•	

			13-28			· .
	29	22	15	<b>∞</b>	1	Dece
	30 100 T	23 1000	16 100	9	2	ecember
	31	24	17	10	3	Тие
		25 .75-G	18	11	4	Wed
		26	19	12	5	Thu
		27	20	13	6	Fri
2002		28	21	14	7	Sat

							_
	26	19	12	\ \		Sun	
							ي چ
				1			
	27 exemp	20	13 160 ST .75 G	10		Mon	anuarv
	1	C: VII	6 A			١ ،	
	C 40	770	13047	\			
	28	21	14	\ 1		Tue	
	* -		-				
				\			
	29 25 G	256	15	<b>√</b> ∞	\ <b>—</b>	Wed	
		र्यार					
	€	TOAT	AZCUT	\	\		
	30	23	115	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	7	Thu	
	4. 1.	4	AY				
				\			
	31		17	10	W	Fri	
_	<b>O</b>	<u>}</u>	_	,			
2		ICH!	NEWT	`\			
		25	18	11	4	Sat	
				. /			
			12-255		\		

.

 		15-2			
26	19	12	SI	Sun	Jan
27	20	13 1CCT	61000	Mon	anuary
28	21	14	7	Tue	
29	22	15	· 25-G	Wed	
30	23	16	9	Thu 2	
31	24	17	25·G	Fri	
	25	18		<b>♣</b>	

	J	

		15-58			
26	19	12	SI	Sun	January
27	20	13 10cT	6 100 T	Mon	lary
28	21	14	7	Tine	
29	22	15	\$ .78.€	Wed	
30	23	16	9	Thu 2	
31	24	17	10	33	
	25	120		A Sat	

•

<u> </u>			<u> </u>		<del></del>			
		1		L9-	-21	A AW		
	,		<del>prod</del>		72	12 V		2003
	Sai	1					\$	
		Sa Pillara Arabana		·		W. Am	M April	
	i.		<u>Ö</u>	Page 2	7	77	17 W	
	Fri	w/		-	(4	9-	ds	
					i i	8	7	
	Тhи	~	6		23	CREAN.	CREAM	
				£ .		35 (	35 (	
	1					j		
	Wed	kanne,	$\infty$	<b>1</b>	22	29	Clear	
						0	750	
	,					er 22		
	Tue		r	kanena An	N	CREAM	CREAM	
							10	
5						. 35	3	
	Моп		9	<del>para</del>	7	27	Clear	
							Am	
	· · · · · · · · · · · · · · · · · · ·						× ×	
	Sun		S		- Processing	97	77	

		N		23	16	<b>V</b> 9	2		Sun	
					0,					Febr
	CLEAR 25 G		CLEAR	ર્યું હ	17	10	CLEAR CLEAR		Mon	uary
	CREAM	H	CREAM	25	18	11	4 Cizeam		Tue	
	CLEAR	U	CLEAR	26	19	12	JS G CLEAR		Wed	
	CREAM		CREAM	27	20	13	6 CREAM		Thu	
	. 25 6	7	. 25° G	28	21	14	7 25 6		Fri	
7007		00		MARCH	22	12-256	~	<b>)</b>	Sat	

	<b>J</b>	

	, 111,00		12-23	·		
,	23	16	9	2	Sun	Feb
	24	17	10	CLEAR	Mon	February
	25	<b>18</b>	11 CR	C. C. C. C. C. C. C. C. C. C. C. C. C. C	Тие	
	26	19	12 CL	CLEAR	Wed	
	27	<b>20</b>	C 3	6 CREAN	Т'nи	
	28	21	14	7	Fri	i
2003		22	15	<b>~</b>	Nat	

	23	16	9	2	Sun	Feb
	24	17	200	<u>့</u> သ	Mon	ebruary
	25	18	11 CR	4	Tue	
	26	19	<b>12</b>	CLEAR	Wed	
	27	20	13	6 CRRAIN	Thu	
	28	21	14	7	Fri	
2003		22	15	8	Sat	

. •

,


Sat	3	89-	22		
777		7	71	80	
Thu	6 CREAM 2SP	13	70	27 CREAM 250	
Wed	5 CLEAR		9	26 CLEAR	
Tue	C Re			25. CREAN 25P	
uery Mon	3 RE SEND 3 OVER NIGHT CLEAR			24 Clear	
February Sum		7	91		
	 				BB0004

C	<b>J</b>	
		•

														٦
3	۲ -	2.48	27	ļ  -	20	Ame 1	13	MIL	6 2			Sun		<u>_</u>
CRN	1 25 T					\$	⊕ <b>દ</b>		25-6 j					
3	200			7		-	Crango Crango	1	Alight 1	U)		, ,		
05		828	28	c	21	المعدد المعن	4	to early	7	50		Mon		
ata			28	e F		المهرا	25. 52	Ş			3			
	~				<u> </u>	4	35 N	\$ 5 °		50		Tue		
		Clar Home		P24	22	Anne A	<u>v</u>	Cream Co	20-L	O	, <u>.</u>	te		
	,	Killiane	Game			A Company		D Alght	£ 8:8 7				ļ	
	~~~	0	· · · · · · · · · · · · · · · · · · ·	~₹	2	FOY	<u>,</u>		3	20	2	Wed		818
		0	30	727	23	CANA E	16	Ame. SD				d		
		3	0h-70			How to car	重集	0						
		the state		30	24		<del></del>	2 S	=	8	w	Thu	~ N	
		e cha	Cycan	PET	42	250	7	F 4	•				72.C	
		Par	· ·					ı •	- 25. - 25. - 25.				27	
		7	~	PAR	25	F	18	<b>T</b>		34.	4	Fri		m A
		6	24°	P .	91			\$						MARCH
0		24	N										20	
2003		A COM	Cane	249	26	7	19	Charle Ca	12	12 Per	S	Sat 2.0	23	
N		AD CADA	3 3		• (			2	74.4			20		
	7	3	W		-	12-	-252		£ 9				20	

.

٠.		<u> </u>					
五二	31/7	24 100 Test	17	10 40 FIRC	2	To the Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal Royal	Sum (16)
26/18	TO THE	25	18	11	4	/ 120	Mon (V)
The state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the s	1CC TEST Z	\	1940 Flac 4 ATP 873   50 mg T3	12	5   CC Test 2 73	125	Tue Tue
2/2	A Motor		20	13	640 Flac	7 20	The B B
28/18	. 28 X	28	21 40 Fmc	14	7 2 7 3	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	Thu the day
Ky.	X Extra State of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of t	29	22	15	8 40 FIR	$\nabla$	The Up Park (IE)
La H	32.	30	23 (10 PM)	-223	9 2 43	$\sim$ $1$	Ser Car



							Initials Date
						Prepared By  Approved By	
o ₩IESCR JOI	NES 57506 CalumnWike-Is-						
			T		4	5	e
		1			TOST E	.P.T	70.4
					10.01	1-1-1-1	Rectio
	Barry B.					<del>                                      </del>	
11/2010	- CATTO 13.	lobiai		<del>                                      </del>	140	1012	13
	500150n	100 145	Tien	1,25		1100	
3/4/01	5 Ocus 0 N	100155				1   14	
	17 Dous off	0.404			<del>╟┤┤┊┤┤</del> ┋	11+++	<del></del>
112/12	K G L L C T	100135	Trevi	1,5	82	26	1113a
194101	50gus Alth					1 000	1 3'X
5/8/01	0095	100000 -	Hoc	1.60		11111	++++-
10101				110	<del>║┤╎</del> ┤┤┤	<del>                                     </del>	
	Charlie					+   +   -	
1/19/01	Dre	100137	Tren	1.5	430	1110	1130
12410	Post sous	10013 BE	Fren	115		0.0	
10.110	3						
	Fluin						
2/101	4Days on	100140	Teen	.25	37	2.6	14
3501	1100,00	100 159	Trea	1,2	14g		
3/2010	Pre	100165			86	19	45
490	Post Hoaks	100172	100	i.a	16.3	69	2.4
	Tim M Je	Oct 12 Carl					
10/1/2	S Days aft	100146	Tres	, 25	1007	19.6	5.1
2/16/01	Fours on on	100157			11/8	2,9	3.0
	100 L OY4						
, ,	Jon off						
2146	Pre	100152	meck	11.5	1626	1/1/1	35
3/15/	110au	100153	Drups	5	575	<b>a</b> 0.4	8.6
यो खें	14000000	11.56		5	95	484	9.0
	<u>ت</u>				**		
	<u> </u>	ļ ;				1 1 1	
2 0	Pre	100166		4	8.5 44	33	1 85
3341	Pos-1	100167	3 70	4	H		11 40
4501		100171		44444	5.3	11114	3.8
411101		160173	1 13 1	20	3,1	0.0	
	`				#- - - - - - -		
	CAIVIN						
3/26/01	asospie	100176			33.7	145.4	82
416/01	a" tost	100176	19-286	70C	4.5 17.a	100 4.0	4.0
4124101	4 Doses	100181	$\mathcal{L}_{\mathcal{L}_i}$	700	1 17.a	1140	1 4.0

€: WILSON JONES G7506 ColumnWai	(			Prepared By Approved By	Initials Date
	1 2 2	3	4	=	6
Mon I clear Tu Tue Two cx	to crema				
Tue Two cry	2 Me 1/2 G C.	100359	10/2/0	.3	39.0
10/17/01 Pre TIE	PINE	100400	143	0	o
100se 12 Thur 15	a 4-105 N C.	100402			
10/20 mon 10 THE	1 Clear	100410	2.6	0,0	0
11/801 33		100434	116.2	8.0	3.0
13 D 13 D 11/101 BAZE 1.46		100417	0.4//	44.0	2,3
11/201 BASE		1,064912-	2.5	3, 2	09
Romo 10/4/01					
2 weeks of Cla	Ca ST	10045t	56.7	2.3	34.6
poloi Pre		100467	4.8	17,0	<u>                                  </u>
10/25 DG		100413 100507	1 a.v	<sup>2</sup> 30.2 <b>6.3</b>	3
11/3/01 Pase line	7-2992	1004123 100475	2.2	90.4	0

		26				Prepared By	Initials	Date
	,	<i>J</i>				Approved By		
WILSON .	JONES G7506 ColumnWrite ®	·	2					; <u> </u>
	No. ora				T			· ——
			Pather	Marie Born		( J		
		4	Contrapor Con Pt			Same -		
					<u> </u>	1	<del>, , , , , , , , , , , , , , , , , , , </del>	
!	m collins	10540	50	3	13	B. C.		
	1/22	100551	11110			111/11		
							1111	$\top$
		++++++			├ <b>ा</b> <del>-</del> - <del> </del>		+++	++
							<del>                                     </del>	+
	ZANAMA	100541		90	as	108	1111	4
	1/22	100550	<u>    zsa  </u>	58	33	0.8		
								7
			<u> </u>					7
		<del>                                      </del>						++
	Se remu neg	1/4547				<del>                                     </del>		+
	nea )	100556		25	S	1111		$\bot$
	3		_					
( )			11/1/1		115	1110	++++	++
J/15	les Dwain	100942	1 600	1 1 1 1 1	1 1 1 1 1	110	<del></del>	
						<del>                                     </del>		
								ļ
	GARY S.	10000	6.4-	3.5	2.3	1 1 1 1		
	1 3 4 3 V			3			++++	++
		100557				_		++
						<del></del>		
								$\perp \downarrow$
								j. <u> </u>
	Kerren Toth	100544	25	25	6	1: 42		
	Keven Toth 31503	100561						$\Box$
	310103		<del></del>				1111	11
-		<del></del>			┝┼┼╌┼┼╌┈╫╌			-++
		<del>  - - - - - </del>			<del>┞┋┋</del>			
								1!
	BARRY B	100545	7_	/0	4	2.5		
	214/03	100552		5	Ó	-		
						,	!	
						1		
	-							-
				<u> </u>		1 .   .	1 1	
	SASON moderate nondrolog	100546	10	5_	3	1.3	1144	
	moderate					1:		Ш
	New Acolor							
	7.01.01	100555			5			
	neg			(40)	<del>                                      </del>			$\sqcap \uparrow$
			7-3026				+ + + + -	-

					Prepared 8	
AILSON JONES G7506 ColumnValle N						
			O X Y	metho		0 G 10 1
Tom Tognet		100548	1 1	1 54	149	<del>                                     </del>
10th 10gne		100598	700	-   -   -   -   -   -   -   -   -   -		
						3
						4
						5
Almando P normaj	CS					б
normal	102553				1113	//.C '
						8
					++++-	9
marin B						10
	102654		<b>5</b>		+ + + + + + + + + + + + + + + + + + + +	12
110141061	7000		<u> </u>			13
						14
		m	<b>ब</b> ी 40	40		15
Benito 28	100558			H		16
2-8						16 (17
						18
				<del>                                     </del>		19
100,160,100						20
mikemai	100559					21 22
						23
						24
BON 84 E						25
30004 E	22					26
	100560					27
						29
						29
!		! ! !	! ! ! !			30
	<u> </u>		H=7-4		+++	31
		<u> </u>		╫╌┼┼┼	++++-	33
	77777		Hitt			34
						35
0 -13 01						36
1 X11 1000						37
NOW THE						38
Les Andres						39
		7-30	27			40

						- Brancend Bir	Initials	Date
						Prepared By		
WILSOF JO	NES G7506 ColumnWrite 4					Approved By		
			2		4	5	6	
		<del> </del>	<del> </del>	<del> </del>				
					<del></del>	<del>-                                    </del>	1 1 1	TI
	Maryin B.							
1331	Marvin B. Pre	190177		4120	27.4	44.7		16
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	. )							$\top$
:	,						++++	+
	,	<del>                                     </del>		╟ <del>┼</del> ┼┊┽╏╅╍╫┪	<del></del>		┝┼┼	
-	,							<del>    -</del>
					<del>                                      </del>			<del>   </del>
				╫┼┼┼┼	<del></del>			+
					1 1 1 1			
	Dury 1 G.							11
	Pre Hauloi	100186			00			00
	1/2/66	100305			10,4	969		1
			╫┽╀╬┼╌	<del>╿</del> ╏┼┊┞ <del>┊╏</del> ╸╣┪	43		<del> - - - -</del>	11,
	10/25/01	100413	╫┽┼┼┼╌		<del>                                      </del>	32012		i i
	<u>C</u> 3							
5/076	Pre 88 13	100150		4. 1	: 56.0	13		243
1	76/17	100205		480	37.6	98		3.8
		100452		48.0 608	30.8	8.7		3.5
	11/28/01	10000	$\parallel + + + + + + + -$			- Ort		20
		<del>                                     </del>						,
	Romo							
5/   /	PR-P	100193			90	7.5		ua
1-1-1		1,000	TOC				ПП	
		<del>  -</del>				1111		+
				╫┽╌┼┼┼┼	<del>╏┧╅╅</del> ╌╫┯			
		1 1 1						+-
	Chrystic G.					1		Н.
5 80		locaca	TOC		1.5	198		Ja
1								
		<del>                                     </del>	#		<del>                                      </del>			++-
			1 1	!			1 1 1	+-
	RamonC			-				-
5/3/101	Two doses	100003	TOC	.a	1/0F1.3	_ <u> </u>		2,7
0 0	II	100307			1165	69.0		117
4,7,1	1 16 Cm 5 off	100334			1516	6414		4.6
an A	1 10 000 2 04-	100334	#	<del>                                     </del>			1:11	17.1
			111111				++++	+
	BACKL						+++	
6127		100331			166	5.5 0.0		30
, m	17 Days 044	locuou			iG	0.0		+
<u>-</u>	11300							
		$H + \cdots + \cdots$	7-30				++++	+
								1 1

m 5 100109

Chastie Gaines 100113

100125 10 pays of 10010 100132 on pays

Latasha 100115

Barry Bond 100121

Bob 100128 A 1/8/01 Trem

Paul Three 100129 1/8/01 Tren 100130 1/8/01

Three days

Mary's Friend 100131 15/00

100132 1/8/00

	<b>J</b>	
	•	

## BARRY

\$BLOOD TEST NOV 29, FEB 14, MARCH 28.

# G" I Box off Season 4 2 Box souton

\* Depo test Cyp 3 Bottles off & Res Section

\* Clear & CREAM off & Rea Season \$200

\$ Clamberro est to Reg 100 pills

TOTAL

\$ 2500

C	<b>J</b>	
	·	

Citation number:

STAMP

PLACE

2 3 8 2 6

	J	

	<u> </u>	

GARy/11-27 - Ree (1-28 - C- 40 tittle o 11-30-02 40,0 little am 2-2-02 Icc T/ 40-6 little one 11-91